<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy - Tsujimoto, Y - 2021 | Cochrane Library</title> <meta content="Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy - Tsujimoto, Y - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013330.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy - Tsujimoto, Y - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013330.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013330.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy" name="citation_title"/> <meta content="Yasushi Tsujimoto" name="citation_author"/> <meta content="yssh0108@yahoo.co.jp" name="citation_author_email"/> <meta content="Sho Miki" name="citation_author"/> <meta content="Sumitomo Hospital" name="citation_author_institution"/> <meta content="Hiroki Shimada" name="citation_author"/> <meta content="Kobe City Medical Center General Hospital" name="citation_author_institution"/> <meta content="Hiraku Tsujimoto" name="citation_author"/> <meta content="Hyogo Prefectural Amagasaki General Medical Center" name="citation_author_institution"/> <meta content="Hideto Yasuda" name="citation_author"/> <meta content="Jichi Medical University Saitama Medical Center" name="citation_author_institution"/> <meta content="Yuki Kataoka" name="citation_author"/> <meta content="Tomoko Fujii" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD013330.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013330.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013330.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013330.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Acute Kidney Injury [prevention &amp; control]; Blood Coagulation; *Continuous Renal Replacement Therapy; Kidney; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013330.pub2&amp;doi=10.1002/14651858.CD013330.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="UDgTyLGV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013330\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013330\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013330.pub2",title:"Non\\u2010pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy",firstPublishedDate:"Sep 14, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013330.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013330.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013330.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013330.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013330.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013330.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013330.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013330.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013330.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013330.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2663 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013330.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-sec-0110"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/appendices#CD013330-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/supinfo/CD013330StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/supinfo/CD013330StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#CD013330-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Yasushi Tsujimoto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#CD013330-cr-0005">Sho Miki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#CD013330-cr-0006">Hiroki Shimada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#CD013330-cr-0007">Hiraku Tsujimoto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#CD013330-cr-0008">Hideto Yasuda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#CD013330-cr-0009">Yuki Kataoka</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information#CD013330-cr-0010">Tomoko Fujii</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information/en#CD013330-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013330.pub2">https://doi.org/10.1002/14651858.CD013330.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013330-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013330-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013330-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013330-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013330-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013330-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013330-abs-0001" lang="en"> <section id="CD013330-sec-0001"> <h3 class="title" id="CD013330-sec-0001">Background</h3> <p>Acute kidney injury (AKI) is a common complication amongst people who are critically ill, and it is associated with an increased risk of death. For people with severe AKI, continuous kidney replacement therapy (CKRT), which is delivered over 24 hours, is needed when they become haemodynamically unstable. When CKRT is interrupted due to clotting of the extracorporeal circuit, the delivered dose is decreased and thus leading to undertreatment. </p> </section> <section id="CD013330-sec-0002"> <h3 class="title" id="CD013330-sec-0002">Objectives</h3> <p>This review assessed the efficacy of non‐pharmacological measures to maintain circuit patency in CKRT. </p> </section> <section id="CD013330-sec-0003"> <h3 class="title" id="CD013330-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 25 January 2021 which includes records identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. </p> </section> <section id="CD013330-sec-0004"> <h3 class="title" id="CD013330-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) (parallel‐group and cross‐over studies), cluster RCTs and quasi‐RCTs that examined non‐pharmacological interventions to prevent clotting of extracorporeal circuits during CKRT.  </p> </section> <section id="CD013330-sec-0005"> <h3 class="title" id="CD013330-sec-0005">Data collection and analysis</h3> <p>Three pairs of review authors independently extracted information including participants, interventions/comparators, outcomes, study methods, and risk of bias. The primary outcomes were circuit lifespan and death due to any cause at day 28. We used a random‐effects model to perform quantitative synthesis (meta‐analysis). We assessed the risk of bias in included studies using the Cochrane Collaboration’s tool for assessing the risk of bias. Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD013330-sec-0006"> <h3 class="title" id="CD013330-sec-0006">Main results</h3> <p>A total of 20 studies involving 1143 randomised participants were included in the review. The methodological quality of the included studies was low, mainly due to the unclear randomisation process and blinding of the intervention. We found evidence on the following 11 comparisons: (i) continuous venovenous haemodialysis (CVVHD) versus continuous venovenous haemofiltration (CVVH) or continuous venovenous haemodiafiltration (CVVHDF); (ii) CVVHDF versus CVVH; (iii) higher blood flow (≥ 250 mL/minute) versus standard blood flow (&lt; 250 mL/minute); (iv) AN69 membrane (AN69ST) versus other membranes; (v) pre‐dilution versus post‐dilution; (vi) a longer catheter (&gt; 20 cm) placing the tip targeting the right atrium versus a shorter catheter (≤ 20 cm) placing the tip in the superior vena cava; (vii) surface‐modified double‐lumen catheter versus standard double‐lumen catheter with identical geometry and flow design; (viii) single‐site infusion anticoagulation versus double‐site infusion anticoagulation; (ix) flat plate filter versus hollow fibre filter of the same membrane type; (x) a filter with a larger membrane surface area versus a smaller one; and (xi) a filter with more and shorter hollow fibre versus a standard filter of the same membrane type. </p> <p>Circuit lifespan was reported in 9 comparisons. Low certainty evidence indicated that CVVHDF (versus CVVH: MD 10.15 hours, 95% CI 5.15 to 15.15; 1 study, 62 circuits), pre‐dilution haemofiltration (versus post‐dilution haemofiltration: MD 9.34 hours, 95% CI ‐2.60 to 21.29; 2 studies, 47 circuits; I² = 13%), placing the tip of a longer catheter targeting the right atrium (versus placing a shorter catheter targeting the tip in the superior vena cava: MD 6.50 hours, 95% CI 1.48 to 11.52; 1 study, 420 circuits), and surface‐modified double‐lumen catheter (versus standard double‐lumen catheter: MD 16.00 hours, 95% CI 13.49 to 18.51; 1 study, 262 circuits) may prolong circuit lifespan. However, higher blood flow may not increase circuit lifespan (versus standard blood flow: MD 0.64, 95% CI ‐3.37 to 4.64; 2 studies, 499 circuits; I² = 70%). More and shorter hollow fibre filters (versus standard filters: MD ‐5.87 hours, 95% CI ‐10.18 to ‐1.56; 1 study, 6 circuits) may reduce circuit lifespan. </p> <p>Death from any cause was reported in four comparisons We are uncertain whether CVVHDF versus CVVH, CVVHD versus CVVH or CVVHDF, longer versus a shorter catheter, or surface‐modified double‐lumen catheters versus standard double‐lumen catheters reduced death due to any cause, in very low certainty evidence. </p> <p>Recovery of kidney function was reported in three comparisons. We are uncertain whether CVVHD versus CVVH or CVVHDF, CVVHDF versus CVVH, or surface‐modified double‐lumen catheters versus standard double‐lumen catheters increased recovery of kidney function. </p> <p>Vascular access complications were reported in two comparisons. Low certainty evidence indicated using a longer catheter (versus a shorter catheter: RR 0.40, 95% CI 0.22 to 0.74) may reduce vascular access complications, however, the use of surface‐modified double lumen catheters versus standard double‐lumen catheters may make little or no difference to vascular access complications. </p> </section> <section id="CD013330-sec-0007"> <h3 class="title" id="CD013330-sec-0007">Authors' conclusions</h3> <p>The use of CVVHDF as compared with CVVH, pre‐dilution haemofiltration, a longer catheter, and surface‐modified double‐lumen catheter may prolong the circuit lifespan, while higher blood flow and more and shorter hollow fibre filter may reduce circuit life. The overall certainty of the evidence was assessed to be low to very low due to the small sample size of the included studies. </p> <p>Data from future rigorous and transparent research are much needed in order to fully understand the effects of non‐pharmacological interventions in preventing circuit coagulation amongst people with AKI receiving CKRT. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013330-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013330-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013330-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013330-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013330-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013330-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013330-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013330-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013330-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013330-abs-0002" lang="en"> <h3>Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous kidney replacement therapy </h3> <p><b>What is the issue?</b> </p> <p>Acute kidney injury (AKI) is a major problem in people with severe illness. In cases of severe AKI, kidney replacement therapy/dialysis (KRT) using circuits is necessary. Continuous kidney replacement therapy is performed continuously over 24 hours. Clotting of the CKRT circuit can interfere with this treatment. To prevent this, a variety of non‐pharmacological (not using medication) interventions have been studied. We aimed to summarise current evidence regarding the efficacy of non‐pharmacological interventions for preventing clotting of extracorporeal circuits during CKRT. </p> <p><b>What did we do?</b> </p> <p>We searched for available evidence from the Cochrane Kidney and Transplant Specialised Register up to 25 January 2021. Our review summarised the results of 20 randomised studies involving a total of 1143 people. </p> <p><b>What did we find?</b> </p> <p>We found that the quality of the 20 included studies was low, and the number randomised was small. The majority of the included studies did not report death as an outcome. We found that continuous venovenous haemodiafiltration (CVVHDF), as compared with continuous venovenous haemofiltration (CVVH), may prolong circuit lifespan. In addition, pre‐dilution haemofiltration, as compared with post‐dilution haemofiltration, a longer catheter placing the tip at the right atrium, as compared with a shorter catheter placing the tip in the superior vena cava, and surface‐modified double lumen catheter, as compared with standard double lumen catheter, may extend the circuit lifespan. However, higher blood flow compared to standard blood flow rate might not affect circuit lifespan. Overall, the data was limited and of very low certainty. </p> <p><b>Conclusions</b> </p> <p>We found that the effects of non‐pharmacological interventions in people with AKI receiving CKRT remain unclear. There is a need for studies assessing CKRT circuit lifespan as well as other clinically important outcomes. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013330-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013330-sec-0116"></div> <h3 class="title" id="CD013330-sec-0117">Implications for practice</h3> <section id="CD013330-sec-0117"> <p>Current evidence shows that the following non‐pharmacological strategies: CVVHDF, pre‐dilution haemofiltration, longer catheter, and surface‐modified double‐lumen catheter, may extend circuit lifespan during CKRT. On the other hand, a filter with more and shorter hollow fibres may reduce circuit lifespan. Analyses revealed that applying a higher blood flow may not alter circuit life. The available evidence is limited and thus we are unable to draw any solid conclusions in regards to the role and impact of the other non‐pharmacological interventions for preventing circuit clotting amongst people receiving CKRT. </p> </section> <h3 class="title" id="CD013330-sec-0118">Implications for research</h3> <section id="CD013330-sec-0118"> <p>Recent clinical practice guidelines did not address the use of non‐pharmacological interventions for maintaining circuit patency (<a href="./references#CD013330-bbs2-0088" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements2012;2(2):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO Acute Kidney Injury Work Group 2012</a>). Current evidence is limited and thus further high‐quality RCTs are needed to provide a more comprehensive assessment before anyone particular non‐pharmacological intervention is to be recommended for clinical practice. Our review illustrates that any research into non‐pharmacological methods should be prospective, randomised, adequately powered, and transparently reported. Furthermore, future studies should not only consider circuit lifespan as an outcome measure but also other patient‐important outcomes including death. We remain cautious as to the appropriateness of a cross‐over study design for future studies in this field due to systematic differences between the two periods of the cross‐over studies are highly likely, which may lead to a higher risk of bias; a potentially higher rate of drop‐outs/losses to follow‐up after the first period is also likely due to high death rates in the critically ill patients in the ICU settings. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013330-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013330-sec-0008"></div> <div class="table" id="CD013330-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CVVHD versus CVVH or CVVHDF for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CVVHD compared to CVVH or CVVHDF for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting: </b> ICU<br/><b>Intervention:</b> CVVHD<br/><b>Comparison:</b> CVVH or CVVHDF </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVH or CVVHDF</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVHD</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Circuit lifespan</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause</p> <p>Follow up: 24 hours to 90 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1,000<br/>(225 to 751) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77<br/>(0.42 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> <p>Follow up: ICU discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1,000<br/>(67 to 402) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/>(0.37 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CVVHD:</b> continuous venovenous haemodialysis; <b>CVVH:</b> continuous venovenous haemofiltration; <b>CVVHDF:</b> continuous venovenous haemodiafiltration; <b>CKRT:</b> continuous kidney replacement therapy;<b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval;<b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious inconsistency </p> <p><sup>3</sup> Downgraded one level due to serious indirectness (death at the longest follow‐up) </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CVVHDF versus CVVH for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CVVHDF versus CVVH for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> CVVHDF<br/><b>Comparison:</b> CVVH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVHDF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with CVVH was 8.55 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with CVVHDF was 10.15 hours higher (5.15 to 15.15 higher) than CVVH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1,000<br/>(316 to 547) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.52 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>714 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>786 per 1,000<br/>(614 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/>(0.86 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>2,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CVVHD:</b> continuous venovenous haemodialysis; <b>CVVH:</b> continuous venovenous haemofiltration; CKRT: continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> <p><sup>3</sup> Downgraded one level due to serious concern of publication bias </p> <p><sup>4</sup> Downgraded two levels due to very serious risk of bias (participants were excluded from analyses if died) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pre‐dilution versus post‐dilution (as defined by study investigators) for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Pre‐dilution versus post‐dilution (as defined by study investigators) for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> pre‐dilution<br/><b>Comparison:</b> post‐dilution </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with post‐dilution</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pre‐dilution</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with post‐dilution was 22.5 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with pre‐dilution was 9.34 hours higher (2.60 lower to 21.29 higher) than post‐dilution </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Higher blood flow versus standard blood flow for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Higher versus standard blood flow for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> higher blood flow<br/><b>Comparison:</b> standard blood flow </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard blood flow</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with higher blood flow</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with standard blood flow was 17.2 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with higher blood flow was 0.64 hours higher (3.37 lower to 4.64 higher) than standard blood flow </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious inconsistency </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Long (&gt; 20 cm) versus short (≤ 20 cm) catheter for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Long (&gt; 20 cm) versus short (≤ 20 cm) catheter for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> long catheter (&gt; 20 cm)<br/><b>Comparison:</b> short catheter (≤ 20 cm) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with short catheter (≤ 20cm)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with long catheter (&gt; 20 cm)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with short catheters was 17.5 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with longer catheters was 6.5 hours higher (1.48 to 11.52 higher) than short catheters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>402 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1,000<br/>(104 to 529) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38<br/>(0.61 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular access complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>511 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1,000<br/>(102 to 368) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.38<br/>(0.20 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious indirectness (used ICU death as a surrogate endpoint) </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision </p> <p><sup>4</sup> Downgraded one level due to serious imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> surface‐modified double‐lumen catheter<br/><b>Comparison:</b> standard double‐lumen catheter with identical geometry and flow design </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard double‐lumen catheter with identical geometry and flow design</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surface‐modified, double‐lumen catheter</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with standard double‐lumen catheters was 118 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with surface‐modified double‐lumen catheters was 16 hours higher (13.49 to 18.51 higher) than standard double‐lumen catheters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>331 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1,000<br/>(251 to 506) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08<br/>(0.76 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Very low <sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>492 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1,000<br/>(344 to 590) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/>(0.70 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular access complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000<br/>(7 to 92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/>(0.09 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> <p><sup>3</sup> Downgraded one level due to serious indirectness (used ICU mortality as a surrogate) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Polyethylenimine‐treated membrane (AN69ST) versus other membranes for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Polyethylenimine‐treated AN69ST versus other membranes for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> polyethylenimine‐treated AN69ST<br/><b>Comparison:</b> other membranes </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with other membrane</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polyethylenimine‐treated AN69ST</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with other membranes was 14.1 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with polyethylenimine‐treated AN69ST was 1.54 hours higher (4.53 lower to 7.6 higher) than other membranes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Flat plate versus hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Flat plate versus hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AKI receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> flat plate filter<br/><b>Comparison:</b> hollow fibre filter (of the same membrane type) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hollow fibre filter of the same membrane type</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with flat plate filter</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with hollow fibre filters was 17.1 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with flat plate filters was 1.4 hours lower (12.12 lower to 9.32 higher) than hollow fibre filters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013330-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">More and shorter versus standard hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>More and shorter versus standard hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> more and shorter hollow fibre filter<br/><b>Comparison:</b> standard hollow fibre filter </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard hollow fibre filter of the same membrane type</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with more and shorter fibre filters</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with standard hollow fibre filters was 21.27 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with more and shorter fibre filters was 5.87 hours lower (10.18 to 1.56 lower) than standard hollow fibre filters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular access complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013330-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013330-sec-0009"></div> <section id="CD013330-sec-0010"> <h3 class="title" id="CD013330-sec-0010">Description of the condition</h3> <p>Acute kidney injury (AKI) is defined as an abrupt decline in kidney function with increased serum creatinine or decreased urine output (<a href="./references#CD013330-bbs2-0088" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements2012;2(2):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO Acute Kidney Injury Work Group 2012</a>). AKI occurs in nearly half of the admitted cases in intensive care units (ICUs) and is related to increased death (<a href="./references#CD013330-bbs2-0071" title="BouchardJ , AcharyaA , CerdaJ , MaccarielloER , MadarasuRC , TolwaniAJ , et al. A prospective international multicenter study of AKI in the intensive care unit. Clinical Journal of the American Society of Nephrology: CJASN2015;10(8):1324-31. [MEDLINE: 26195505]">Bouchard 2015</a>; <a href="./references#CD013330-bbs2-0077" title="FujiiT , UchinoS , DoiK , SatoT , KawamuraT , JAKID study group. Diagnosis, management, and prognosis of patients with acute kidney injury in Japanese intensive care units: the JAKID Study. Journal of Critical Care2018;47:185-91. [MEDLINE: 30015288]">Fujii 2018</a>; <a href="./references#CD013330-bbs2-0086" title="HosteEA , BagshawSM , BellomoR , CelyCM , ColmanR , CruzDN , et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Medicine2015;41(8):1411-23. [MEDLINE: 26162677]">Hoste 2015</a>; <a href="./references#CD013330-bbs2-0094" title="NisulaS , KaukonenKM , VaaraST , KorhonenAM , PoukkanenM , KarlssonS , et al. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Medicine2013;39(3):420-8. [MEDLINE: 23291734]">Nisula 2013</a>). For people with severe AKI, kidney replacement therapy (KRT) is required to manage electrolytes, fluid balance, and waste products. Previous epidemiological studies revealed that the need for KRT accounted for 16% to 24% of people with AKI in the ICUs (<a href="./references#CD013330-bbs2-0077" title="FujiiT , UchinoS , DoiK , SatoT , KawamuraT , JAKID study group. Diagnosis, management, and prognosis of patients with acute kidney injury in Japanese intensive care units: the JAKID Study. Journal of Critical Care2018;47:185-91. [MEDLINE: 30015288]">Fujii 2018</a>; <a href="./references#CD013330-bbs2-0094" title="NisulaS , KaukonenKM , VaaraST , KorhonenAM , PoukkanenM , KarlssonS , et al. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Medicine2013;39(3):420-8. [MEDLINE: 23291734]">Nisula 2013</a>). </p> <p>Administration of KRT can be achieved either intermittently or continuously. Although intermittent KRT removes fluids more rapidly, it has been suggested to cause hypotension and further damage to kidney function (<a href="./references#CD013330-bbs2-0091" title="MannsM , SiglerMH , TeehanBP . Intradialytic renal haemodynamics - potential consequences for the management of the patient with acute renal failure. Nephrology Dialysis Transplantation1997;12(5):870-2. [MEDLINE: 9175035]">Manns 1997</a>; <a href="./references#CD013330-bbs2-0099" title="SilversidesJA , PintoR , KuintR , WaldR , HladunewichMA , LapinskySE , et al. Fluid balance, intradialytic hypotension, and outcomes in critically ill patients undergoing renal replacement therapy: a cohort study. Critical Care (London, England)2014;18(6):624. [MEDLINE: 25407408]">Silversides 2014</a>). Moreover, deranged electrolyte levels, which are frequently observed in people with AKI, are normalised more successfully when KRT is administered continuously (<a href="./references#CD013330-bbs2-0101" title='UchinoS , FealyN , BaldwinI , MorimatsuH , BellomoR . Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Medicine2003;29(4):575-8. [MEDLINE: 12577144]'>Uchino 2003</a>). Accordingly, continuous kidney replacement therapy (CKRT) is recommended for people with AKI who are haemodynamically unstable, and it is a technique used most frequently in the ICU setting (<a href="./references#CD013330-bbs2-0071" title="BouchardJ , AcharyaA , CerdaJ , MaccarielloER , MadarasuRC , TolwaniAJ , et al. A prospective international multicenter study of AKI in the intensive care unit. Clinical Journal of the American Society of Nephrology: CJASN2015;10(8):1324-31. [MEDLINE: 26195505]">Bouchard 2015</a>; <a href="./references#CD013330-bbs2-0077" title="FujiiT , UchinoS , DoiK , SatoT , KawamuraT , JAKID study group. Diagnosis, management, and prognosis of patients with acute kidney injury in Japanese intensive care units: the JAKID Study. Journal of Critical Care2018;47:185-91. [MEDLINE: 30015288]">Fujii 2018</a>; <a href="./references#CD013330-bbs2-0088" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements2012;2(2):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO Acute Kidney Injury Work Group 2012</a>). A multicentre survey conducted in 33 countries showed that 75.2% of KRT sessions were conducted using the CKRT approach (<a href="./references#CD013330-bbs2-0086" title="HosteEA , BagshawSM , BellomoR , CelyCM , ColmanR , CruzDN , et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Medicine2015;41(8):1411-23. [MEDLINE: 26162677]">Hoste 2015</a>). </p> <p>The choice of CKRT modalities varies across the world. An international observational study in 2007 reported that continuous venovenous haemofiltration (CVVH) had been widely used (<a href="./references#CD013330-bbs2-0102" title="UchinoS , BellomoR , MorimatsuH , MorgeraS , SchetzM , TanI , et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Medicine2007;33(9):1563-70. [MEDLINE: 17594074]">Uchino 2007</a>). However, another small observational study showed comparable small and mid‐sized molecular solute removal between CVVH and continuous venovenous haemodialysis (CVVHD) (<a href="./references#CD013330-bbs2-0096" title="RicciZ , RoncoC , BachetoniA , D'amicoG , RossiS , AlessandriE , et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Critical Care (London, England)2006;10(2):R67. [MEDLINE: 16646985]">Ricci 2006</a>). Evidence supporting a clear choice of one CKRT modality over others remains inconclusive although the use of various diffusion‐based techniques, such as CVVHD and continuous venovenous haemodiafiltration (CVVHDF), has been reported in a recent observational study (<a href="./references#CD013330-bbs2-0077" title="FujiiT , UchinoS , DoiK , SatoT , KawamuraT , JAKID study group. Diagnosis, management, and prognosis of patients with acute kidney injury in Japanese intensive care units: the JAKID Study. Journal of Critical Care2018;47:185-91. [MEDLINE: 30015288]">Fujii 2018</a>). </p> <p>In clinical practice, CKRT is typically provided through a double‐lumen venous catheter as a continuous 24‐hour therapy; however, CKRT may also operate for 21‐23 hours a day in different clinical settings (<a href="./references#CD013330-bbs2-0092" title="MehtaRL , McDonaldB , GabbaiFB , PahlM , PascualMT , FarkasA , et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney International2001;60(3):1154-63. [MEDLINE: 11532112]">Mehta 2001</a>; <a href="./references#CD013330-bbs2-0101" title='UchinoS , FealyN , BaldwinI , MorimatsuH , BellomoR . Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Medicine2003;29(4):575-8. [MEDLINE: 12577144]'>Uchino 2003</a>; <a href="./references#CD013330-bbs2-0104" title="VesconiS , CruzDN , FumagalliR , Kindgen-MillesD , MontiG , MarinhoA , et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Critical Care (London, England)2009;13(2):R57. [MEDLINE: 19368724]">Vesconi 2009</a>). Reasons for the interruption of CKRT could be clotting of the extracorporeal circuits, clogging of the membrane, or the need for transportation to outside of the ICU settings, such as to the operation theatre or the radiology department for imaging tests. Such treatment interruptions decrease the delivered CKRT dose, leading to insufficient uraemic control (<a href="./references#CD013330-bbs2-0076" title="FealyN , BaldwinI , BellomoR . The effect of circuit “down-time” on uraemic control during continuous veno-venous haemofiltration. Critical Care &amp; Resuscitation2002;4(4):266-70. [MEDLINE: 16573439]">Fealy 2002</a>; <a href="./references#CD013330-bbs2-0093" title="MitchellA , DaulAE , BeiderlindenM , SchafersRF , HeemannU , KribbenA , et al. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clinical Nephrology2003;59(2):106-14. [MEDLINE: 12608553]">Mitchell 2003</a>). A small single‐centre study indicated that circuit clotting was the primary reason for the shortened circuit life (<a href="./references#CD013330-bbs2-0103" title="VenkataramanR , KellumJA , PalevskyP . Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. Journal of Critical Care2002;17(4):246-50. [MEDLINE: 12501152]">Venkataraman 2002</a>). Undoubtedly, exchanging the circuits due to circuit failure leads to increased medical costs and the workload of healthcare professionals (<a href="./references#CD013330-bbs2-0076" title="FealyN , BaldwinI , BellomoR . The effect of circuit “down-time” on uraemic control during continuous veno-venous haemofiltration. Critical Care &amp; Resuscitation2002;4(4):266-70. [MEDLINE: 16573439]">Fealy 2002</a>; <a href="./references#CD013330-bbs2-0092" title="MehtaRL , McDonaldB , GabbaiFB , PahlM , PascualMT , FarkasA , et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney International2001;60(3):1154-63. [MEDLINE: 11532112]">Mehta 2001</a>). Thus, treatment interruption is widely considered a key quality indicator for CKRT (<a href="./references#CD013330-bbs2-0095" title="RewaOG , VilleneuvePM , LachanceP , EurichDT , StelfoxHT , GibneyRT , et al. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review. Intensive Care Medicine2017;43(6):750-63. [MEDLINE: 27730284]">Rewa 2017</a>). </p> </section> <section id="CD013330-sec-0011"> <h3 class="title" id="CD013330-sec-0011">Description of the intervention</h3> <p>The primary intervention to maintain the patency of the CKRT circuit is anticoagulation. A previous multicentre trial showed that as many as half of the critically‐ill study subjects were treated with CKRT without the use of any anticoagulation (<a href="./references#CD013330-bbs2-0057" title="BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low-intensity and high-intensity continuous renal replacement therapy [Erratum in: Crit Care Resusc. 2014 Jun;16(2):139]. Critical Care &amp; Resuscitation2014;16(1):34-41. [MEDLINE: 24588434]BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036]BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized Evaluation of Normal versus Augmented Level of Replacement Therapy (RENAL) trial. Blood Purification2014;37(4):325-34. [MEDLINE: 25171270]BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase-FielitzA , LicariE , et al. Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429-36. [MEDLINE: 23306586]BellomoR , MartenssonJ , KaukonenKM , LoS , GallagherM , CassA , et al. Epidemiology of RBC transfusions in patients with severe acute kidney injury: analysis from the Randomized Evaluation of Normal Versus Augmented Level Study. Critical Care Medicine2016;44(5):892-900. [MEDLINE: 26619086]BellomoR , MartenssonJ , LoS , KaukonenKM , CassA , GallagherM , et al. Femoral access and delivery of continuous renal replacement therapy dose. Blood Purification2016;41(1-3):11-7. [MEDLINE: 26485539]BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?Kidney International2006;70(7):1202-4. [MEDLINE: 16988729]CassA , BellomoR , ColeL , FinferS , GallagherM , LoS , et al. Intensity of continuous renal replacement therapy in critically ill patients with severe acute kidney injury [abstract no: O78]. Nephrology2009;14(Suppl 1):A21. FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58-66. [MEDLINE: 19281446]GallagherM , BellomoR , CassA , ColeL , FinferS , LeeJ , et al. Fluid balance and patient outcomes in AKI: analysis of the RENAL study participants [abstract no: 128]. Nephrology2011;16(Suppl 1):57. [EMBASE: 70532476]GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post-RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45. [EMBASE: 71377309]GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666]GallagherMP , BellomoR , CassA , ColeL , LeeJY , LoSN , et al. Fluid balance and patient outcomes in AKI: analysis of the RENAL study participants [abstract no: SA-PO2521]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):698A. GallagherMP , BellomoR , CassA , GattasD , LeeJY , LoSN , et al. Long term outcomes of severe AKI: results of the post-RENAL study [abstract no: SA-OR008]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):67A. JunM , BellomoR , CassA , GallagherM , LoS , LeeJ , et al. Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study. Critical Care Medicine2014;42(8):1756-65. [MEDLINE: 24717460]JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29. [EMBASE: 71377246]JunM , BellomoR , CassA , GallagherMP , LoSN . Timing of renal replacement therapy and outcomes in critically III patients with acute kidney injury in the randomized evaluation of normal versus augmented level of replacement therapy therapy trial [abstract no: TH-OR038]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):8A. LinJ , GallagherM , BellomoR , DuanM , TrongtrakulK , WangAY , et al. SOFA coagulation score and changes in platelet counts in severe acute kidney injury: analysis from the randomized evaluation of normal versus augmented level (RENAL) study. Nephrology2019;24(5):518-25. [MEDLINE: 29693303]LinJ , WangY , BellomoR , DuanML , GallagherMP . SOFA coagulation score and patient outcomes in severe acute kidney injury: analysis from the randomized evaluation of normal versus augmented level (RENAL) study [abstract]. Nephrology2017;22(Suppl 3):51. [EMBASE: 618236384]LinJ , WangY , BellomoR , DuanML , GallagherMP . SOFA coagulation score and patient outcomes in severe AKI: analysis from the Randomised Evaluation of Normal versus Augmented Level (RENAL) study [abstract no: PUB049]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):976-7. [EMBASE: 633701676]MuruganR , KertiSJ , ChangCH , GallagherM , ClermontG , PalevskyPM , et al. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration: a secondary analysis of the Randomized Evaluation of Normal vs Augmented Level (RENAL) of Renal Replacement Therapy trial. JAMA Network Open2019;2(6):e195418. [MEDLINE: 31173127]O'BrienZ , CassA , ColeL , FinferS , GallagherM , McArthurC , et al. Higher versus lower continuous renal replacement therapy intensity in critically ill patients with liver dysfunction. Blood Purification2018;45(1-3):36-43. [MEDLINE: 29161684]O'BrienZ , CassA , ColeL , FinferS , GallagherM , McArthurC , et al. Sex and mortality in septic severe acute kidney injury. Journal of Critical Care2019;49:70-6. [MEDLINE: 30388491]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , LoS , et al. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627-38. [MEDLINE: 19846848]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753-60. [MEDLINE: 22610181]RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199-205. [MEDLINE: 19256108]RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407-16. [MEDLINE: 18856012]RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236]RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576]WangA , LoS , BellomoR , CassA , GallagherM . Ace inhibitor use and AKI outcomes: an analysis of the randomised evaluation of normal vs augmented level of replacement therapy (RENAL) trial [abstract no: 104]. Nephrology2013;18(Suppl 1):41. [EMBASE: 71357086]WangAY , BellomoR , CassA , FinferS , GattasD , MyburghJ , et al. Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes. Nephrology2015;20(7):492-8. [MEDLINE: 25891297]WangAY , BellomoR , CassA , MyburghJ , FinferS , GattaD , et al. Predictors of health-related quality of life in survivors following acute kidney injury: a secondary analysis of post-RENAL study outcomes [abstract no: SP117]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii107-8. [EMBASE: 71491744]WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin-converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617-22. [MEDLINE: 24894685]WangAY , TrongtrakulK , BellomoR , LiQ , CassA , GallagherM , et al. HMG-CoA reductase inhibitors (statins) and acute kidney injury: a secondary analysis of renal study outcomes. Nephrology2019;24(9):912-8. [MEDLINE: 31058387]WangY , LoSN , GallagherMP , LiQ , CassA , MyburghJA , et al. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence [abstract no: SA-OR105]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):86A. XieY , LinJ , GallagherM , BellomoR , WangX , JardineM , et al. Prognostic significance of low level of blood glucose in severe acute kidney injury: a secondary analysis from the RENAL study [abstract no: SP243]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i425. [EMBASE: 622604949]">RENAL 2006</a>). Indeed, anticoagulation therapy is associated with a substantial risk of bleeding, which in itself is a common feature amongst people who are critically ill. Research efforts have recently shifted to identify effective and safe anticoagulants, e.g. citrate, as well as strategies to minimise the risk of clotting without using anticoagulants during CKRT. Since there is an existing Cochrane review exploring the effects of pharmacological interventions in CKRT (<a href="./references#CD013330-bbs2-0100" title="TsujimotoH , TsujimotoY , NakataY , FujiiT , TakahashiS , AkazawaM , et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD012467. [DOI: 10.1002/14651858.CD012467.pub3]">Tsujimoto 2020</a>), our present review aimed to focus on non‐pharmacological strategies for circuit survival. </p> <p>Clotting of CKRT circuits is attributed to stasis or turbulence of blood flow, haemoconcentration, or activation of the intrinsic coagulation system by blood–tube, blood–air, or blood–filter contact (<a href="./references#CD013330-bbs2-0057" title="BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low-intensity and high-intensity continuous renal replacement therapy [Erratum in: Crit Care Resusc. 2014 Jun;16(2):139]. Critical Care &amp; Resuscitation2014;16(1):34-41. [MEDLINE: 24588434]BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036]BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized Evaluation of Normal versus Augmented Level of Replacement Therapy (RENAL) trial. Blood Purification2014;37(4):325-34. [MEDLINE: 25171270]BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase-FielitzA , LicariE , et al. Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429-36. [MEDLINE: 23306586]BellomoR , MartenssonJ , KaukonenKM , LoS , GallagherM , CassA , et al. Epidemiology of RBC transfusions in patients with severe acute kidney injury: analysis from the Randomized Evaluation of Normal Versus Augmented Level Study. Critical Care Medicine2016;44(5):892-900. [MEDLINE: 26619086]BellomoR , MartenssonJ , LoS , KaukonenKM , CassA , GallagherM , et al. Femoral access and delivery of continuous renal replacement therapy dose. Blood Purification2016;41(1-3):11-7. [MEDLINE: 26485539]BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?Kidney International2006;70(7):1202-4. [MEDLINE: 16988729]CassA , BellomoR , ColeL , FinferS , GallagherM , LoS , et al. Intensity of continuous renal replacement therapy in critically ill patients with severe acute kidney injury [abstract no: O78]. Nephrology2009;14(Suppl 1):A21. FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58-66. [MEDLINE: 19281446]GallagherM , BellomoR , CassA , ColeL , FinferS , LeeJ , et al. Fluid balance and patient outcomes in AKI: analysis of the RENAL study participants [abstract no: 128]. Nephrology2011;16(Suppl 1):57. [EMBASE: 70532476]GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post-RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45. [EMBASE: 71377309]GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666]GallagherMP , BellomoR , CassA , ColeL , LeeJY , LoSN , et al. Fluid balance and patient outcomes in AKI: analysis of the RENAL study participants [abstract no: SA-PO2521]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):698A. GallagherMP , BellomoR , CassA , GattasD , LeeJY , LoSN , et al. Long term outcomes of severe AKI: results of the post-RENAL study [abstract no: SA-OR008]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):67A. JunM , BellomoR , CassA , GallagherM , LoS , LeeJ , et al. Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study. Critical Care Medicine2014;42(8):1756-65. [MEDLINE: 24717460]JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29. [EMBASE: 71377246]JunM , BellomoR , CassA , GallagherMP , LoSN . Timing of renal replacement therapy and outcomes in critically III patients with acute kidney injury in the randomized evaluation of normal versus augmented level of replacement therapy therapy trial [abstract no: TH-OR038]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):8A. LinJ , GallagherM , BellomoR , DuanM , TrongtrakulK , WangAY , et al. SOFA coagulation score and changes in platelet counts in severe acute kidney injury: analysis from the randomized evaluation of normal versus augmented level (RENAL) study. Nephrology2019;24(5):518-25. [MEDLINE: 29693303]LinJ , WangY , BellomoR , DuanML , GallagherMP . SOFA coagulation score and patient outcomes in severe acute kidney injury: analysis from the randomized evaluation of normal versus augmented level (RENAL) study [abstract]. Nephrology2017;22(Suppl 3):51. [EMBASE: 618236384]LinJ , WangY , BellomoR , DuanML , GallagherMP . SOFA coagulation score and patient outcomes in severe AKI: analysis from the Randomised Evaluation of Normal versus Augmented Level (RENAL) study [abstract no: PUB049]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):976-7. [EMBASE: 633701676]MuruganR , KertiSJ , ChangCH , GallagherM , ClermontG , PalevskyPM , et al. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration: a secondary analysis of the Randomized Evaluation of Normal vs Augmented Level (RENAL) of Renal Replacement Therapy trial. JAMA Network Open2019;2(6):e195418. [MEDLINE: 31173127]O'BrienZ , CassA , ColeL , FinferS , GallagherM , McArthurC , et al. Higher versus lower continuous renal replacement therapy intensity in critically ill patients with liver dysfunction. Blood Purification2018;45(1-3):36-43. [MEDLINE: 29161684]O'BrienZ , CassA , ColeL , FinferS , GallagherM , McArthurC , et al. Sex and mortality in septic severe acute kidney injury. Journal of Critical Care2019;49:70-6. [MEDLINE: 30388491]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , LoS , et al. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627-38. [MEDLINE: 19846848]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753-60. [MEDLINE: 22610181]RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199-205. [MEDLINE: 19256108]RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407-16. [MEDLINE: 18856012]RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236]RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576]WangA , LoS , BellomoR , CassA , GallagherM . Ace inhibitor use and AKI outcomes: an analysis of the randomised evaluation of normal vs augmented level of replacement therapy (RENAL) trial [abstract no: 104]. Nephrology2013;18(Suppl 1):41. [EMBASE: 71357086]WangAY , BellomoR , CassA , FinferS , GattasD , MyburghJ , et al. Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes. Nephrology2015;20(7):492-8. [MEDLINE: 25891297]WangAY , BellomoR , CassA , MyburghJ , FinferS , GattaD , et al. Predictors of health-related quality of life in survivors following acute kidney injury: a secondary analysis of post-RENAL study outcomes [abstract no: SP117]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii107-8. [EMBASE: 71491744]WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin-converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617-22. [MEDLINE: 24894685]WangAY , TrongtrakulK , BellomoR , LiQ , CassA , GallagherM , et al. HMG-CoA reductase inhibitors (statins) and acute kidney injury: a secondary analysis of renal study outcomes. Nephrology2019;24(9):912-8. [MEDLINE: 31058387]WangY , LoSN , GallagherMP , LiQ , CassA , MyburghJA , et al. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence [abstract no: SA-OR105]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):86A. XieY , LinJ , GallagherM , BellomoR , WangX , JardineM , et al. Prognostic significance of low level of blood glucose in severe acute kidney injury: a secondary analysis from the RENAL study [abstract no: SP243]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i425. [EMBASE: 622604949]">RENAL 2006</a>). Therefore, non‐pharmacological interventions to prevent clotting of the CKRT circuit generally include the strategic selection of a catheter or access site, optimising the blood flow rate, CKRT modalities, and methods of haemodilution. </p> </section> <section id="CD013330-sec-0012"> <h3 class="title" id="CD013330-sec-0012">How the intervention might work</h3> <p>The selection of a catheter and access site may play a significant role in determining circuit life. According to Poiseuille's Law, for fluid/blood flow through an intravenous (IV) catheter a thick and short catheter may be theoretically preferable to avoid stasis. In addition, to avoid kinking or curving of the catheter, which may lead to impaired blood flow, the right jugular venous route may be preferable as it is straight and easily monitored by bedside clinical staff. </p> <p>In CKRT, blood flow rates are typically set at 100 to 200 mL/minute or based on a filtration ratio. In fact, the pump used in CKRT delivers blood with peristaltic revolutions, and the flow rate is, in effect, the rate of the pump revolution. An observational study revealed a forward and backward blood flow path between the pump and filter, which may cause blood flow stasis (<a href="./references#CD013330-bbs2-0070" title="BaldwinI , BellomoR , KochB . Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Medicine2004;30(11):2074-9. [MEDLINE: 15448889]">Baldwin 2004</a>). Considering the potential blood flow fluctuations due to the peristaltic roller pump, maintaining the blood flow at a high rate may be useful to prevent CKRT filter clotting. </p> <p>Regarding the choice of CKRT modalities, filtration may shorten the circuit lifetime compared to dialysis by haemoconcentration due to its ultrafiltration process (<a href="./references#CD013330-bbs2-0096" title="RicciZ , RoncoC , BachetoniA , D'amicoG , RossiS , AlessandriE , et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Critical Care (London, England)2006;10(2):R67. [MEDLINE: 16646985]">Ricci 2006</a>). During filtration, haematocrit levels increase and consequently elevate the risk of coagulation in the filter. In CVVH and CVVHDF, substitution fluids can be administered before (pre‐dilution) or after (post‐dilution) filtration. Pre‐dilution CKRT aims to decrease haemoconcentration and improve blood flow. This may improve filter lifespan and efficiency, leading to less treatment interruptions and better clearance. However, a critical aspect of pre‐dilution therapies is the relationship between the blood flow rate and replacement fluid rate (<a href="./references#CD013330-bbs2-0073" title="ClarkWR , LeblancM , RicciZ , RoncoC . Quantification and dosing of renal replacement therapy in acute kidney injury: areappraisal. Blood Purification2017;44(2):140-55. [MEDLINE: 28586767]">Clark 2017</a>). Pre‐dilution may also reduce molecular clearance when the blood flow is low, and its precise clinical impact upon people who are critically ill is currently unclear. </p> </section> <section id="CD013330-sec-0013"> <h3 class="title" id="CD013330-sec-0013">Why it is important to do this review</h3> <p>Circuit failure during CKRT affects the actual delivery of CKRT, which leads to decreased treatment efficiency. Moreover, it increases the associated medical costs and workload of clinical staff. Thus, maintaining the patency of the CKRT circuit is particularly crucial in ICU settings. This review aimed to provide a clinically relevant and solid body of evidence to assist healthcare decision‐making when delivering CKRT in critical care medicine. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013330-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013330-sec-0014"></div> <p>This review assessed the efficacy of non‐pharmacological measures to maintain circuit patency during CKRT. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013330-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013330-sec-0015"></div> <section id="CD013330-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013330-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all parallel‐group and cross‐over randomised controlled trials (RCTs), cluster‐randomised trials and quasi‐randomised trials (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) investigating non‐pharmacological interventions for preventing clotting of extracorporeal circuits during CKRT. We excluded observational studies, case reports, reviews, editorials, and commentaries. </p> </section> <section id="CD013330-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with AKI who received CKRT in the ICU settings regardless of age or sex. In this review, we defined AKI according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition and staging system (<a href="./references#CD013330-bbs2-0088" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements2012;2(2):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO Acute Kidney Injury Work Group 2012</a>). </p> </section> <section id="CD013330-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD013330-sec-0020"> <h5 class="title">Dialysis modalities</h5> <p> <ul id="CD013330-list-0001"> <li> <p>CVVHD versus CVVH or CVVHDF</p> </li> <li> <p>CVVHDF versus CVVH</p> </li> <li> <p>Pre‐dilution versus post‐dilution (as defined by study investigators)</p> </li> </ul> </p> </section> <section id="CD013330-sec-0021"> <h5 class="title">Blood flow rate</h5> <p> <ul id="CD013330-list-0002"> <li> <p>Higher (≥ 250 mL/minute) blood flow versus standard (&lt; 250 mL/minute) blood flow</p> </li> </ul> </p> </section> <section id="CD013330-sec-0022"> <h5 class="title">Catheter types</h5> <p> <ul id="CD013330-list-0003"> <li> <p>Long (&gt; 20 cm) catheter versus short (≤ 20 cm) catheter</p> </li> <li> <p>Left‐sided catheters versus right‐sided catheter</p> </li> <li> <p>Surface‐modified double‐lumen catheter versus standard double‐lumen catheter with identical geometry and flow design </p> </li> </ul> </p> </section> <section id="CD013330-sec-0023"> <h5 class="title">Membrane types</h5> <p> <ul id="CD013330-list-0004"> <li> <p>Polyethylenimine‐treated polyacrylonitrile membrane (AN69ST) versus other types of membrane </p> </li> <li> <p>Heparin‐grafted membrane versus other membranes</p> </li> <li> <p>A flat plate filter versus a hollow fibre filter of the same membrane type</p> </li> <li> <p>A filter with a larger membrane surface area versus a smaller one</p> </li> <li> <p>A filter with more and shorter hollow fibres versus a standard filter of the same membrane type </p> </li> </ul> </p> </section> <section id="CD013330-sec-0024"> <h5 class="title">Access sites</h5> <p> <ul id="CD013330-list-0005"> <li> <p>Internal jugular access versus femoral access</p> </li> <li> <p>Subclavian venous versus superior vena cava as the line tip portion in the same access catheter insertion site </p> </li> <li> <p>Subclavian venous versus right atrium as the line tip portion in the same access catheter insertion site </p> </li> <li> <p>Superior vena cava versus right atrium as the line tip portion in the same access catheter insertion site </p> </li> </ul> </p> </section> <section id="CD013330-sec-0025"> <h5 class="title">Other types of non‐pharmacological interventions</h5> <p> <ul id="CD013330-list-0006"> <li> <p>Single‐site infusion anticoagulation versus double‐site infusion anticoagulation</p> </li> <li> <p>Infusion anticoagulation from access line versus pre‐filter single site</p> </li> <li> <p>Saline flushing versus no saline flushing.</p> </li> </ul> </p> <p>We intended to compare the effects of one non‐pharmacological intervention to another. We included studies that used or did not use anticoagulants in both intervention and control groups. We excluded studies comparing non‐pharmacological interventions to pharmacological interventions. </p> </section> </section> <section id="CD013330-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD013330-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013330-list-0007"> <li> <p>Circuit lifespan (commences at the point of starting CKRT and concludes upon circuit cessation for any reason) </p> </li> <li> <p>Death (any cause) at day 28 of follow‐up or last reported time point</p> </li> </ul> </p> </section> <section id="CD013330-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013330-list-0008"> <li> <p>Recovery of kidney function: numbers of participants assessed as free of KRT at day 28, 90, and 180 of follow‐up </p> </li> <li> <p>Vascular access complications: functions (e.g. ability to use CKRT, uninterrupted use without the need for any intervention, percentage change in access blood flow) or access‐site infections (e.g. those suspected to be catheter‐related) requiring antibiotic therapy </p> </li> <li> <p>Costs related to health care services (unit: USD, calculated rate 1 USD = 0.93 Euro)</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid</p> </li> </ul> </p> </section> </section> </section> <section id="CD013330-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013330-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 25 January 2021 through contact with the Cochrane Kidney and Transplant Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD013330-list-0009"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals, and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the WHO International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the Cochrane Kidney and Transplant website under <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">CKT Register of Studies</a>. </p> <p>See <a href="./appendices#CD013330-sec-0122">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD013330-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We screened reference lists of narrative review articles, relevant studies, and clinical practice guidelines for additional relevant information. Where appropriate, we contacted experts and professional organisations in the field for information on unpublished or incomplete/ongoing studies. </p> <p>Due to resource constraints, we did not consider grey literature sources (e.g. conference abstracts, dissertations, and theses) additional to those already included in the Cochrane Kidney and Transplant Register of Studies. </p> </section> </section> <section id="CD013330-sec-0032"> <h3 class="title" id="CD013330-sec-0032">Data collection and analysis</h3> <section id="CD013330-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Two authors (YT and SM) independently screened the titles and abstracts obtained from the literature search in duplicate, and clearly irrelevant records were excluded. Studies that might include relevant data or information were retained initially for subsequent assessment where the two authors independently assessed the full texts of these potentially eligible studies against our prespecified inclusion/exclusion criteria. We arranged for non‐English and non‐Japanese study reports to be translated before full assessment. Disagreements were resolved by discussion with a third author acting as an arbiter (TF)<b>.</b> </p> </section> <section id="CD013330-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by three pairs of review authors (YT and SM, YK and HS, HY and HT) in duplicate, using pre‐standardised data extraction forms. We resolved disagreements by discussion with another author acting as an arbiter (TF). Where more than one record from the same study existed, records were grouped together and the record with the most complete data was identified as the primary reference of the study. We specifically highlighted discrepancies between available study protocols and final published reports where appropriate. </p> </section> <section id="CD013330-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three pairs of review authors (YT and SM, YK and HS, HY and HT) assessed the risk of bias in included studies using the Cochrane Collaboration’s tool for assessing the risk of bias (<a href="./references#CD013330-bbs2-0085" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>) (see <a href="./appendices#CD013330-sec-0123">Appendix 2</a>). Any disagreement was resolved by discussion with another author acting as an arbiter (TF). </p> <p>The Cochrane Collaboration’s tool for assessing the risk of bias considered six aspects of bias: (i) selection bias; (ii) performance bias; (iii) detection bias; (iv) attrition bias; (v) reporting bias; and (vi) other bias. </p> <p> <ul id="CD013330-list-0010"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD013330-list-0011"> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Was the study report free of potential selective outcome reporting (reporting bias)?</p> </li> </ul> </p> <p>For assessing other potential threats to validity ('Other bias'), we assumed that the use of anticoagulation therapy or sedative agents were important co‐interventions in this review. Additionally, we judged how baseline imbalance of anticoagulation affected treatment effect estimates. </p> <p> <ul id="CD013330-list-0012"> <li> <p>Was the study apparently free of other problems that could put it at risk of bias (e.g. co‐intervention of anticoagulation)? </p> </li> <li> <p>Did baseline imbalance regarding anticoagulation therapy exist?</p> </li> </ul> </p> </section> <section id="CD013330-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. death or recovery of kidney function), treatment effect measures were expressed in risk ratios (RRs) with 95% confidence intervals (CIs). Where continuous scales of measurement were used to assess the effects of treatment interventions (e.g. circuit lifespan, or costs), we calculated mean differences (MDs) with their respective 95% CIs. </p> </section> <section id="CD013330-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>We assessed unit of analysis issues in three possible ways in which they might arise.</p> <section id="CD013330-sec-0038"> <h5 class="title">1. Multiple measurements of the same participants from either individually randomised or cross‐over studies </h5> <p>If there were multiple measurements of the outcomes such as circuit lifespan (e.g. several circuits were used by the same individual due to repeated CKRT using new circuits), unit of analysis issues might arise. We considered addressing these issues by first assessing each included study for any evidence of multiple enrolments (e.g. number of circuits exceeded the number of participants). We then planned to exclude those with multiple measurements by entering the data of only the first circuit, but such information was not available. We, therefore, performed our analysis based on available data as reported, using the total number of circuits as the denominator according to methods employed in a previous study (<a href="./references#CD013330-bbs2-0100" title="TsujimotoH , TsujimotoY , NakataY , FujiiT , TakahashiS , AkazawaM , et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD012467. [DOI: 10.1002/14651858.CD012467.pub3]">Tsujimoto 2020</a>). </p> </section> <section id="CD013330-sec-0039"> <h5 class="title">2. Clustering at the level of the enrolled units in cluster‐randomised studies</h5> <p>In dealing with cluster‐RCTs, for dichotomous data, we would have applied the design effect formula and calculated effective sample size and number of events using the intra‐cluster correlation coefficient (ICC) among each unit and the average cluster size, as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). If the ICC had not been reported, we would have used the ICC of a similar study as a substitute. For continuous data, only the sample size would be reduced; means and standard deviations would remain unchanged (Higgins 2011). </p> </section> <section id="CD013330-sec-0040"> <h5 class="title">3. Randomised cross‐over studies</h5> <p>We considered only data from the first period (before crossing over) where possible. However, for cross‐over studies that did not report first‐phase data, we decided to include the study and analysed the data as if the trials were parallel trials. We rated its validity according to the Cochrane Collaboration’s tool for assessing the risk of bias as being at 'unclear risk of bias' based on baseline imbalance due to the cross‐over design (<a href="#CD013330-sec-0035">Assessment of risk of bias in included studies</a>). </p> </section> <section id="CD013330-sec-0041"> <h5 class="title">Multiple comparisons</h5> <p>All intervention groups that were assessed to be relevant to this review as per our a priori eligibility criteria were included (<a href="#CD013330-sec-0019">Types of interventions</a>). </p> </section> </section> <section id="CD013330-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, we requested further information from the study corresponding authors via electronic or postal mail and any such requested, relevant information obtained were included in the review. We diligently evaluated important numerical data, such as the numbers of screened/randomised participants as well as intention‐to‐treat, as‐treated and per‐protocol populations were reported. Attrition rates, including drop‐outs, losses to follow‐up and withdrawals, were also investigated. Issues of missing data and imputation methods (for example, use of ‘last observation carried forward’ (LOCF)) employed by study investigators were identified and critically appraised (<a href="./references#CD013330-bbs2-0085" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). </p> <p>If studies did not report mean or standard deviation for a continuous outcome, we imputed them from the median and range (<a href="./references#CD013330-bbs2-0087" title="Hozo SP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol2005;5:13.">Hozo 2005</a>) or from the median and interquartile range (<a href="./references#CD013330-bbs2-0106" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol2014;14:135.">Wan 2014</a>). When there was no information on variability, we imputed the standard deviation from other studies in the same meta‐analysis (<a href="./references#CD013330-bbs2-0078" title="Furukawa TA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol2006;59(1):7-10.">Furukawa 2006</a>). </p> </section> <section id="CD013330-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the presence of statistical heterogeneity by visual inspection of the forest plots. We quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD013330-bbs2-0084" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). We followed the guide to the interpretation of I² values as indicated in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD013330-bbs2-0085" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>)/ </p> <p> <ul id="CD013330-list-0013"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test, or confidence intervals for I²) (<a href="./references#CD013330-bbs2-0085" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD013330-sec-0044"> <h4 class="title">Assessment of reporting biases</h4> <p>In this review, since our analyses did not include more than 10 studies, and we could not perform Egger's test or funnel plot symmetry inspection to explore possible small‐study and publication biases (<a href="./references#CD013330-bbs2-0075" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [MEDLINE: 9310563]">Egger 1997</a>). Instead, we investigated the scale of ongoing studies in the field based on the search results from the Cochrane Kidney and Transplant Register of Studies, which includes records from trial registries (WHO ICTRP and ClinicalTrials.gov). </p> </section> <section id="CD013330-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We conducted data synthesis using a random‐effects analytical model.</p> </section> <section id="CD013330-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the protocol, we planned to perform the following subgroup analyses where possible for the primary outcomes to explore possible sources of heterogeneity. However, due to insufficient data, we were unable to pursue the following analyses. </p> <p> <ul id="CD013330-list-0014"> <li> <p>Age of the participants (&lt; 18 years versus ≥ 18 years)</p> </li> <li> <p>Presence or absence of sepsis (<a href="./references#CD013330-bbs2-0090" title="LeviM , SchultzM , van derPollT . Sepsis and thrombosis. Seminars in Thrombosis &amp; Hemostasis2013;39(5):559-66. [MEDLINE: 23625756]">Levi 2013</a>) </p> </li> <li> <p>Pharmacological co‐intervention (citrates, unfractionated heparins, other types of anticoagulation, no anticoagulation). </p> </li> </ul> </p> </section> <section id="CD013330-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>At the protocol stage, we decided to pursue the following sensitivity analyses for the primary outcomes. However, these were not performed for the full review due to limited data. </p> <p> <ul id="CD013330-list-0015"> <li> <p>Repeating the analysis by excluding unpublished studies</p> </li> <li> <p>Repeating the analysis by taking into account the risk of bias in included studies</p> </li> <li> <p>Repeating the analysis by excluding large‐scale studies or studies of long duration</p> </li> <li> <p>Repeating the analysis by excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country </p> </li> <li> <p>Repeating the analysis by including only studies that used the same dosage of anticoagulants in both arms. </p> </li> </ul> </p> </section> <section id="CD013330-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review as 'Summary of findings' tables, created by the <a href="./references#CD013330-bbs2-0080" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 6 May 2020. Available at gradepro.org.">GRADEpro GDT</a> software. These tables present key information concerning the quality/certainty of the evidence, the magnitude of the intervention effects, and the sum of the available data for the main outcomes (<a href="./references#CD013330-bbs2-0097" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE approach (<a href="./references#CD013330-bbs2-0081" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">Guyatt 2008</a>; <a href="./references#CD013330-bbs2-0083" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">Guyatt 2011b</a>), which defines the quality/certainty of a body of evidence as to the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. To assess a body of evidence‐based on the GRADE approach, within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, the precision of effect estimates, and risk of publication bias are important domains for consideration (<a href="./references#CD013330-bbs2-0098" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011b</a>). </p> <p>Our 'Summary of findings' tables illustrated evidence relating to the following outcome measures. </p> <p> <ul id="CD013330-list-0016"> <li> <p>Circuit lifespan</p> </li> <li> <p>Death from any cause at day 28, or last reported time point</p> </li> <li> <p>Recovery of kidney function</p> </li> <li> <p>Vascular access complications.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013330-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013330-sec-0049"></div> <section id="CD013330-sec-0050"> <h3 class="title">Description of studies</h3> <section id="CD013330-sec-0051"> <h4 class="title">Results of the search</h4> <p>Our study selection process of this review is illustrated as a flow diagram in <a href="#CD013330-fig-0001">Figure 1</a>. Our search of the Cochrane Kidney and Transplant Register of Studies identified 69 studies (179 records). After full‐text assessment, 26 studies (37 records) met the eligibility criteria and we excluded 43 studies (142 records). Of these 20 studies were included, five studies are ongoing (<a href="./references#CD013330-bbs2-0069" title="WeidhaseL , deFalloisJ , HausigE , KaiserT , MendeM , PetrosS . Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Critical Care (London, England)2020;24(1):644. [MEDLINE: 33176824]">Weidhase 2020</a>; <a href="./references#CD013330-bbs2-0065" title="KoynerJ . Continuous venovenous hemofiltration versus continuous venovenuous hemodialysis [A comparison of the efficacy of continuous venovenous hemofiltration versus continuous venovenous hemodialysis for renal replacement therapy in acute kidney injury]. clinicaltrials.gov/ct2/show/NCT01062984 (first received 4 February 2010). ">NCT01062984</a>; <a href="./references#CD013330-bbs2-0066" title="ChuaHR . Efficacy and safety of heparin-grafted membrane for CRRT (CARROM) [Continuous renal replacement therapy with anticoagulation-free regimen in bleeding-risk patients using oXiris membrane - CARROM Study]. clinicaltrials.gov/ct2/show/NCT01779635 (first received 30 January 2013). ">NCT01779635</a>; <a href="./references#CD013330-bbs2-0067" title="RieraJS . Impact of CVVHD with adsorption capacity membranes in septic acute kidney injury [Impact of a continuous dialysis technique associated with adsorption capacity membranes in patients with sepsis associated - acute kidney injury]. clinicaltrials.gov/ct2/show/NCT01790620 (first received 13 February 2013). ">NCT01790620</a>; <a href="./references#CD013330-bbs2-0068" title="RimmeleT . Endotoxins and cytokines removal during continuous hemofiltration with oXiris (ECRO). clinicaltrials.gov/ct2/show/NCT03426943 (first received 8 February 2018). ">NCT03426943</a>), and one study is awaiting classification (<a href="./references#CD013330-bbs2-0064" title="AllaouchicheB . Pilot, prospective, multicentric, open study: use of a new Prismaflex filter (coated with heparin) without any addition of heparin in the extracorporeal circuit. Study with direct individual benefit. https://doi.org/10.1186/ISRCTN026745502006. ">ISRCTN02674550</a>). These six studies will be assessed in a future update of this review. </p> <div class="figure" id="CD013330-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013330-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013330-sec-0052"> <h4 class="title">Included studies</h4> <p>Details of our included studies are summarised in the '<a href="./references#CD013330-sec-0133" title="">Characteristics of included studies</a>' tables. These 20 studies randomised 1143 participants. Of these, four studies (57 participants) did not report any of our prespecified outcome measures (<a href="./references#CD013330-bbs2-0001" title="AlamartineE , deFilippisJP , ToulonJ , BerthouxF . On-line continuous venovenous hemodiafiltration: a technique for the control of ultrafiltration and convection during continuous renal replacement therapy. Renal Failure1994;16(6):707-14. [MEDLINE: 7899582]">Alamartine 1994a</a>; <a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>; <a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a>; <a href="./references#CD013330-bbs2-0019" title="WynckelA , CornilletJ , BeneB , StolzA , LepouseC , ParisB , et al. Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO Journal2004;50(1):81-4. [MEDLINE: 14763496]">Wynckel 2004</a>) and were thus excluded from subsequent quantitative synthesis (meta‐analysis). We, therefore, eventually included 16 studies (1072 participants) in our quantitative synthesis. Of these, one study was published only as a conference abstract (<a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>). </p> <section id="CD013330-sec-0053"> <h5 class="title">Study design</h5> <p>Of the 20 included studies, nine were parallel‐group RCTs (<a href="./references#CD013330-bbs2-0001" title="AlamartineE , deFilippisJP , ToulonJ , BerthouxF . On-line continuous venovenous hemodiafiltration: a technique for the control of ultrafiltration and convection during continuous renal replacement therapy. Renal Failure1994;16(6):707-14. [MEDLINE: 7899582]">Alamartine 1994a</a>; <a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>); and 11 were cross‐over RCTs (<a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a>; <a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>; <a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>; <a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>; <a href="./references#CD013330-bbs2-0009" title="KellumJA , JohnsonJP , KramerD , PalevskyP , BradyJJ , PinskyMR . Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Critical Care Medicine1998;26(12):1995-2000. [MEDLINE: 9875910]">Kellum 1998</a>; <a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD013330-bbs2-0019" title="WynckelA , CornilletJ , BeneB , StolzA , LepouseC , ParisB , et al. Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO Journal2004;50(1):81-4. [MEDLINE: 14763496]">Wynckel 2004</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>). </p> </section> <section id="CD013330-sec-0054"> <h5 class="title">Sample size</h5> <p>Included studies were small in scale, with sample size ranging from 6 to 236 participants, with five studies involving 100 or more participants (<a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>). </p> </section> <section id="CD013330-sec-0055"> <h5 class="title">Settings</h5> <p>The majority of the included studies were conducted in the USA, Europe, and Australia in the early 2000s. All the reported study settings were ICUs. </p> </section> <section id="CD013330-sec-0056"> <h5 class="title">Participants</h5> <p>All but one study included adults (mean age 50.5 to 72.7 years) with kidney failure requiring CKRT; <a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a> included only paediatric participants. In nine studies, APACHE II was used for defining severity score, for which the mean score ranged from 18.5 to 27.  The causes of AKI differed between studies, with sepsis being the major cause in 11 studies (<a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>; <a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>; <a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>); in two studies, the main cause of AKI was surgical procedures (<a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>). </p> </section> <section id="CD013330-sec-0057"> <h5 class="title">Interventions and comparators</h5> <p>The comparisons and the corresponding included studies are as follows.</p> <p> <ul id="CD013330-list-0017"> <li> <p>CVVHD versus CVVH or CVVHD: 7 studies (254 participants) (<a href="./references#CD013330-bbs2-0001" title="AlamartineE , deFilippisJP , ToulonJ , BerthouxF . On-line continuous venovenous hemodiafiltration: a technique for the control of ultrafiltration and convection during continuous renal replacement therapy. Renal Failure1994;16(6):707-14. [MEDLINE: 7899582]">Alamartine 1994a</a>; <a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0009" title="KellumJA , JohnsonJP , KramerD , PalevskyP , BradyJJ , PinskyMR . Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Critical Care Medicine1998;26(12):1995-2000. [MEDLINE: 9875910]">Kellum 1998</a>; <a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>; <a href="./references#CD013330-bbs2-0019" title="WynckelA , CornilletJ , BeneB , StolzA , LepouseC , ParisB , et al. Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO Journal2004;50(1):81-4. [MEDLINE: 14763496]">Wynckel 2004</a>). </p> </li> <li> <p>CVVH versus CVVHDF: 2 studies (251 participants) (<a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>). </p> </li> <li> <p>Higher versus standard blood flow: 2 studies (134 participants) (<a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>). </p> </li> <li> <p>Pre‐dilution versus post‐dilution: 2 studies (48 participants) (<a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>). </p> </li> <li> <p>Long (&gt; 20 cm) versus short catheter (≤ 20 cm): 1 study (100 participants) (<a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>). </p> </li> <li> <p>Surface‐modified double‐lumen catheter versus standard double‐lumen catheter of identical geometry and flow design: 1 study (236 participants) (<a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>). </p> </li> <li> <p>Polyethylenimine‐treated AN69 membrane (AN69ST) versus other membranes: 3 studies (76 participants) (<a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>). </p> </li> <li> <p>Filter with more and shorter (21 cm) hollow fibre versus standard (30 cm) hollow fibre: 1 study (6 participants) (<a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>) </p> </li> </ul> </p> <p><a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a> (38 participants) included three separate randomised crossover trials and compared the following non‐pharmacological interventions. </p> <p> <ul id="CD013330-list-0018"> <li> <p>Single‐site versus double‐site infusion anticoagulation</p> </li> <li> <p>Flat plate versus hollow fibre filter of the same membrane type</p> </li> <li> <p>Filter with a larger membrane surface area versus a smaller one.</p> </li> </ul> </p> <p>We could not identify any evidence regarding the other prespecified comparisons as listed in the section '<a href="#CD013330-sec-0019">Types of interventions</a>'. </p> </section> <section id="CD013330-sec-0058"> <h5 class="title">Outcomes</h5> <p>The number of studies and participants that assessed our prespecified outcome measures are summarised as follows (<a href="#CD013330-sec-0026">Types of outcome measures</a>). </p> <p> <ul id="CD013330-list-0019"> <li> <p>Circuit lifespan: 11 studies (663 participants) (<a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a>; <a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>; <a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>). </p> </li> <li> <p>Death from any cause</p> <ul id="CD013330-list-0020"> <li> <p>One study (206 participants) reported death (any cause) at 28 days (<a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>) </p> </li> <li> <p>Three studies (357 participants) reported ICU death (<a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>) </p> </li> <li> <p>Other death‐related outcome measures reported were death at 24 hours (<a href="./references#CD013330-bbs2-0009" title="KellumJA , JohnsonJP , KramerD , PalevskyP , BradyJJ , PinskyMR . Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Critical Care Medicine1998;26(12):1995-2000. [MEDLINE: 9875910]">Kellum 1998</a>), death at 60 days (<a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>), and death at 90 days (<a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>); </p> </li> <li> <p>In three cross‐over trials, the numbers of deaths were reported; however, the numbers of deaths in each study arm were unavailable due to the nature of a cross‐over design (<a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a>; <a href="./references#CD013330-bbs2-0019" title="WynckelA , CornilletJ , BeneB , StolzA , LepouseC , ParisB , et al. Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO Journal2004;50(1):81-4. [MEDLINE: 14763496]">Wynckel 2004</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>). </p> </li> </ul> </li> <li> <p>Recovery of kidney function: 3 studies (304 participants) (<a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>). </p> </li> <li> <p>Vascular access complications: 2 studies (336 participants) (<a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>). </p> </li> <li> <p>Costs to health care services: 2 studies (336 participants) (<a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>). </p> </li> </ul> </p> <p>None of the eligible studies reported the following outcomes: types and number of dialysis filters, circuits and catheters, and consumption of dialysate. </p> </section> </section> <section id="CD013330-sec-0059"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD013330-sec-0134" title="">Characteristics of excluded studies</a>. Reasons for exclusion were wrong population (14 studies) and wrong intervention (29 studies). </p> </section> </section> <section id="CD013330-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD013330-fig-0002">Figure 2</a> and <a href="#CD013330-fig-0003">Figure 3</a> for findings of our risk of bias assessment in the included studies. Overall, the risk of bias across our 20 included studies was judged to be unclear to high. </p> <div class="figure" id="CD013330-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013330-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013330-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013330-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013330-sec-0061"> <h4 class="title">Allocation</h4> <section id="CD013330-sec-0062"> <h5 class="title">Random sequence generation</h5> <p>Four studies were judged to be at low risk of bias: two used computer‐generated randomisation numbers (<a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>), one study used a web‐based randomisation approach (<a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>), and one study used a random number table (<a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>). The remaining studies did not clearly report the method of randomisation and were judged to have an unclear risk of bias. </p> </section> <section id="CD013330-sec-0063"> <h5 class="title">Allocation concealment</h5> <p>Four studies were judged to be at low risk of bias: three used sealed opaque envelopes for the concealment (<a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>), and one used a web‐based randomisation approach (<a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>). The remaining included studies did not clearly report their allocation methods to allow for a precise judgment of their risk of selection bias. </p> </section> </section> <section id="CD013330-sec-0064"> <h4 class="title">Blinding</h4> <p>Two studies blinded the study participants, personnel, and outcome assessors to treatment allocation (<a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>) and were judged to be at low risk of bias for both performance and detection bias. Five studies were judged to be at high risk of both performance and detection bias (<a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>), and nine studies did not provide sufficient information to determine these risks of bias (<a href="./references#CD013330-bbs2-0001" title="AlamartineE , deFilippisJP , ToulonJ , BerthouxF . On-line continuous venovenous hemodiafiltration: a technique for the control of ultrafiltration and convection during continuous renal replacement therapy. Renal Failure1994;16(6):707-14. [MEDLINE: 7899582]">Alamartine 1994a</a>; <a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a>; <a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>; <a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>; <a href="./references#CD013330-bbs2-0009" title="KellumJA , JohnsonJP , KramerD , PalevskyP , BradyJJ , PinskyMR . Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Critical Care Medicine1998;26(12):1995-2000. [MEDLINE: 9875910]">Kellum 1998</a>; <a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>). </p> <p><a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a> blinded study participants and personnel and was judged to be at low risk of performance bias but had unclear detection bias. Three studies were judged to be at high risk of performance bias but at low risk of detection bias (<a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD013330-bbs2-0019" title="WynckelA , CornilletJ , BeneB , StolzA , LepouseC , ParisB , et al. Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO Journal2004;50(1):81-4. [MEDLINE: 14763496]">Wynckel 2004</a>). </p> </section> <section id="CD013330-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Sixteen studies followed all the participants from randomisation to end of the study and were judged to be at low risk of attrition bias (<a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a>; <a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0009" title="KellumJA , JohnsonJP , KramerD , PalevskyP , BradyJJ , PinskyMR . Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Critical Care Medicine1998;26(12):1995-2000. [MEDLINE: 9875910]">Kellum 1998</a>; <a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD013330-bbs2-0019" title="WynckelA , CornilletJ , BeneB , StolzA , LepouseC , ParisB , et al. Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO Journal2004;50(1):81-4. [MEDLINE: 14763496]">Wynckel 2004</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>). We judged two studies to be at high risk of attrition bias due to missing data of more than 10% of the study participants (<a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>), and two studies did not provide sufficient information to determine the risk of bias (<a href="./references#CD013330-bbs2-0001" title="AlamartineE , deFilippisJP , ToulonJ , BerthouxF . On-line continuous venovenous hemodiafiltration: a technique for the control of ultrafiltration and convection during continuous renal replacement therapy. Renal Failure1994;16(6):707-14. [MEDLINE: 7899582]">Alamartine 1994a</a>; <a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>). </p> </section> <section id="CD013330-sec-0066"> <h4 class="title">Selective reporting</h4> <p>We were able to find the study protocols for only 5 of the 18 included studies (<a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>). We judged <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a> to be at high risk of reporting bias because the study did not report our prespecified outcome of death. </p> </section> <section id="CD013330-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>For this review, we also defined two potential sources of bias: baseline imbalance and co‐interventions. Ten studies described baseline characteristics and we judged them to be at low risk of other bias regarding baseline imbalance (<a href="./references#CD013330-bbs2-0001" title="AlamartineE , deFilippisJP , ToulonJ , BerthouxF . On-line continuous venovenous hemodiafiltration: a technique for the control of ultrafiltration and convection during continuous renal replacement therapy. Renal Failure1994;16(6):707-14. [MEDLINE: 7899582]">Alamartine 1994a</a>; <a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0010" title="MaxvoldNJ , SmoyerWE , CusterJR , BunchmanTE . Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Critical Care Medicine2000;28(4):1161-5. [MEDLINE: 10809299]">Maxvold 2000</a>; <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>). </p> <p>For co‐interventions, three studies were judged to be at high risk of bias: the amount of heparin used was different between the two groups in <a href="./references#CD013330-bbs2-0001" title="AlamartineE , deFilippisJP , ToulonJ , BerthouxF . On-line continuous venovenous hemodiafiltration: a technique for the control of ultrafiltration and convection during continuous renal replacement therapy. Renal Failure1994;16(6):707-14. [MEDLINE: 7899582]">Alamartine 1994a</a> and <a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>, and anticoagulant usage and frequency of saline flushing varied between the two groups in <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>. Ten studies were judged to be at low risk of bias (<a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a>; <a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>; <a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD013330-bbs2-0019" title="WynckelA , CornilletJ , BeneB , StolzA , LepouseC , ParisB , et al. Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO Journal2004;50(1):81-4. [MEDLINE: 14763496]">Wynckel 2004</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>) </p> <p>For the remaining studies, we judged them to be at unclear risk of bias due to their cross‐over design. We could not determine whether the baseline characteristics were balanced between the intervention and control groups amongst these cross‐over trials since group‐based baseline information was unavailable. Additionally, we planned to include studies that allocated anticoagulants or sedative agents to both intervention and control arms according to a predefined protocol; however, the majority of the included studies did not report the administration procedures of these treatment options. We decided to include these studies in our review but judged their risk of 'other bias' regarding co‐interventions as per the Cochrane Collaboration's tool for assessing the risk of bias. </p> </section> </section> <section id="CD013330-sec-0068"> <h3 class="title" id="CD013330-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD013330-tbl-0001"><b>Summary of findings 1</b> CVVHD versus CVVH or CVVHDF for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0002"><b>Summary of findings 2</b> CVVHDF versus CVVH for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0003"><b>Summary of findings 3</b> Pre‐dilution versus post‐dilution (as defined by study investigators) for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0004"><b>Summary of findings 4</b> Higher blood flow versus standard blood flow for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0005"><b>Summary of findings 5</b> Long (&gt; 20 cm) versus short (≤ 20 cm) catheter for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0006"><b>Summary of findings 6</b> Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0007"><b>Summary of findings 7</b> Polyethylenimine‐treated membrane (AN69ST) versus other membranes for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0008"><b>Summary of findings 8</b> Flat plate versus hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</a>; <a href="./full#CD013330-tbl-0009"><b>Summary of findings 9</b> More and shorter versus standard hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</a> </p> <p>Please refer to <a href="./full#CD013330-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013330-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013330-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013330-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD013330-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD013330-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD013330-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD013330-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD013330-tbl-0009">summary of findings Table 9</a> for further information on our review findings and corresponding GRADE assessment to assess the certainty of included evidence. </p> <section id="CD013330-sec-0069"> <h4 class="title">Dialysis modalities</h4> <section id="CD013330-sec-0070"> <h5 class="title">CVVHD versus CVVH or CVVHDF</h5> <p>Four studies were included in this comparison (<a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0009" title="KellumJA , JohnsonJP , KramerD , PalevskyP , BradyJJ , PinskyMR . Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Critical Care Medicine1998;26(12):1995-2000. [MEDLINE: 9875910]">Kellum 1998</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>; <a href="./references#CD013330-bbs2-0013" title="Plata-MenchacaEP , Cardenas-CamposP , Moreno-GonzalezG , Corral-VelezV , Vazquez-RebellonJM , Pinseaun-CastilloJP , et al. Comparison of two continuous renal replacement techniques associated with an increased absorption membrane: a randomized control trial [abstract no: 0030]. Intensive Care Medicine Experimental2017;5(Suppl 2):18. [EMBASE: 619044415]Plata-MenchacaEP , Perez-FernandezXL , Estruch-AlrichM , Betbese-RoigA , Cardenas CamposP , Rojas-LoraM , et al. Impact of continuous veno-venous hemodialyisis with an increased adsorption membrane in septic acute kidney injury [abstract no: A325]. Intensive Care Medicine Experimental2016;4(Suppl 1):171. [EMBASE: 617955433]">Plata‐Menchaca 2017</a>). </p> <section id="CD013330-sec-0071"> <h6 class="title">Death from any cause</h6> <p>None of the included studies reported death at 28 days, therefore we synthesised data from the four studies that reported death at the longest follow‐up period (range 24 hours to 90 days). It is uncertain whether CVVHD reduced the risk of death from any cause at the longest follow‐up because the certainty of the evidence was very low (<a href="./references#CD013330-fig-0004" title="">Analysis 1.1</a> (4 studies, 216 participants): RR 0.78, 95% CI 0.41 to 1.39; I² = 78%). </p> </section> <section id="CD013330-sec-0072"> <h6 class="title">Recovery of kidney function</h6> <p>Two studies reported recovery of kidney function at ICU discharge (<a href="./references#CD013330-bbs2-0004" title="DaudKM , LeongGB , VisvanathanR . Acute dialytic support for the critically ill: continuous venovenous haemodialysis versus continuous venovenous haemofiltration. International Medical Journal2006;13(1):37-42. [EMBASE: 43569217]">Daud 2006</a>; <a href="./references#CD013330-bbs2-0012" title="WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - A pilot randomized controlled trial of hemofiltration versus hemodialysis: A Canadian Critical Care Trials Group project. Critical Care (London, England)2012;16(5):R205. [MEDLINE: 23095370]WaldR , FriedrichJO , BagshawSM , BurnsKE , GargAX , HladunewichMA , et al. The optimal mode of renal replacement therapy in acute kidney injury (OMAKI): a pilot randomized controlled trial of CVVH vs CVVHD [abstract no: LB-PO3173]. Journal of the American Society of Nephrology2011;22(Abstracts):10B. ">OMAKI 2012</a>). It is uncertain whether CVVHD increased recovery of kidney function because the certainty of the evidence was very low (<a href="./references#CD013330-fig-0005" title="">Analysis 1.2</a> (2 studies, 93 participants): RR 0.91, 95% CI 0.37 to 2.21; I² = 0%). </p> </section> <section id="CD013330-sec-0073"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported in the four included studies.</p> <p> <ul id="CD013330-list-0021"> <li> <p>Circuit lifespan</p> </li> <li> <p>Vascular access complications</p> </li> <li> <p>Costs</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid.</p> </li> </ul> </p> </section> </section> <section id="CD013330-sec-0074"> <h5 class="title">CVVHDF versus CVVH</h5> <p>Two studies were included in this comparison (<a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0016" title="SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312-7. [MEDLINE: 16850022]SaudanP , NiederbergerM , De SeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN-00724917] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN-00447595] SaudanP , PonteB , PuginJ , MartinP . Improving survival with a greater dialysis dose in patients with AKI: does it depend on early onset of treatment? [abstract no: SU121]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01658135] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long-term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH-PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN-00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186-9. [MEDLINE: 19228754]">Saudan 2006</a>). </p> <section id="CD013330-sec-0075"> <h6 class="title">Circuit lifespan</h6> <p>CVVHDF may increase circuit lifespan when compared with CVVH (<a href="./references#CD013330-fig-0006" title="">Analysis 2.1</a> (1 study, 62 circuits): MD 10.15 hours, 95% CI 5.15 to 15.15; low certainty evidence). </p> </section> <section id="CD013330-sec-0076"> <h6 class="title">Death from any cause at day 28</h6> <p>It is uncertain whether CVVHDF decreased the risk of death from any cause at 28 days compared to CVVH because the certainty of the evidence was very low (<a href="./references#CD013330-fig-0007" title="">Analysis 2.2</a> (1 study 206 participants): RR 0.68, 95% CI 0.52 to 0.90). </p> </section> <section id="CD013330-sec-0077"> <h6 class="title">Recovery of kidney function</h6> <p>It is uncertain whether CVVHDF improved the recovery of kidney function compared to CVVH because the certainty of the evidence was very low (<a href="./references#CD013330-fig-0008" title="">Analysis 2.3</a> (1 study, 96 participants): RR 1.10, 95% CI 0.86 to 1.41). </p> </section> <section id="CD013330-sec-0078"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported in the two included studies.</p> <p> <ul id="CD013330-list-0022"> <li> <p>Vascular access complications</p> </li> <li> <p>Costs</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid.</p> </li> </ul> </p> </section> </section> <section id="CD013330-sec-0079"> <h5 class="title">Pre‐dilution versus post‐dilution (as defined by the study investigators)</h5> <p>Two studies were included in this comparison (<a href="./references#CD013330-bbs2-0006" title="dePontAC , BoumanCS , BakhtiariK , SchaapMC , NieuwlandR , SturkA , et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO Journal2006;52(4):416-22. [MEDLINE: 16883122]">de Pont 2006</a>; <a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>). </p> <section id="CD013330-sec-0080"> <h6 class="title">Circuit lifespan</h6> <p>Pre‐dilution may lead to an extended circuit lifespan compared to post‐dilution (<a href="./references#CD013330-fig-0009" title="">Analysis 3.1</a> (2 studies, 47 circuits): MD 9.34 hours, 95% CI ‐2.60 to 21.29; I² = 13%; low certainty evidence). </p> </section> <section id="CD013330-sec-0081"> <h6 class="title">Costs</h6> <p><a href="./references#CD013330-bbs2-0018" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a> reported the costs of one‐week treatment of CVVH using pre‐ or post‐dilution were 1,817 Euros and 2,146 Euros, respectively. </p> </section> <section id="CD013330-sec-0082"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported in the two included studies.</p> <p> <ul id="CD013330-list-0023"> <li> <p>Death</p> </li> <li> <p>Vascular access complications</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid.</p> </li> </ul> </p> </section> </section> </section> <section id="CD013330-sec-0083"> <h4 class="title">Blood flow rate</h4> <section id="CD013330-sec-0084"> <h5 class="title">Higher (≥ 250 mL/min) versus standard blood flow (&lt; 250 mL/min)</h5> <p>We included two studies for quantitative synthesis (<a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a>). <a href="./references#CD013330-bbs2-0015" title="Ramesh PrasadGV , PalevskyPM , BurrR , LeskoJM , GuptaB , GreenbergA . Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clinical Nephrology2000;53(1):55-60. [MEDLINE: 10661483]">Ramesh Prasad 2000</a> compared standard blood flow (125 mL/min) with 100 mL bolus administration once/hour and augmented blood flow (200 to 250 mL/min) with 100 ml fluid bolus administration once every 30 minutes. We considered this comparison to be eligible for inclusion but rated the study as being at high risk of other bias in terms of co‐interventions. </p> <section id="CD013330-sec-0085"> <h6 class="title">Circuit lifespan</h6> <p>Higher blood flow may make little or no difference to prolonging circuit lifespan compared to standard blood flow (<a href="./references#CD013330-fig-0010" title="">Analysis 4.1</a> (2 studies, 499 circuits): MD 0.64 hours, 95% CI ‐3.37 to 4.64; I² = 70%; low certainty evidence). </p> </section> <section id="CD013330-sec-0086"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported in the two included studies.</p> <p> <ul id="CD013330-list-0024"> <li> <p>Death</p> </li> <li> <p>Recovery of kidney function</p> </li> <li> <p>Vascular access complications</p> </li> <li> <p>Costs</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid.</p> </li> </ul> </p> </section> </section> </section> <section id="CD013330-sec-0087"> <h4 class="title">Catheter types</h4> <section id="CD013330-sec-0088"> <h5 class="title">Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter</h5> <p>One study compared the effects for preventing circuit clotting by either placing the tip of a longer catheter targeting the right atrium versus placing a shorter catheter targeting the tip in the superior vena cava (<a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>). </p> <section id="CD013330-sec-0089"> <h6 class="title">Circuit lifespan</h6> <p>Compared with a shorter catheter, using a longer catheter may prolong circuit lifespan (<a href="./references#CD013330-fig-0011" title="">Analysis 5.1</a> (1 study, 402 circuits): MD 6.50 hours, 95% CI 1.48 to 11.52; low certainty evidence). </p> </section> <section id="CD013330-sec-0090"> <h6 class="title">Death from any cause at day 28</h6> <p>It is uncertain whether a longer catheter reduced the risk of death due to any cause at day 28 compared to a shorter catheter because the certainty of the evidence was very low (<a href="./references#CD013330-fig-0012" title="">Analysis 5.2</a> (1 study, 94 participants): RR 1.38, 95% CI 0.61 to 3.11). </p> </section> <section id="CD013330-sec-0091"> <h6 class="title">Vascular access complications</h6> <p>Compared with shorter catheters, the use of a longer catheter may reduce the risk of vascular access complications (<a href="./references#CD013330-fig-0013" title="">Analysis 5.3</a> (1 study, 94 participants): RR 0.40, 95% CI 0.22 to 0.74; low certainty evidence). </p> </section> <section id="CD013330-sec-0092"> <h6 class="title">Costs</h6> <p><a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a> reported that potential cost reduction using a longer catheter targeting the right atrium was 427 USD per person (95% CI 61 to 794) when compared with a shorter catheter targeting the superior vena cava. </p> </section> <section id="CD013330-sec-0093"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported.</p> <p> <ul id="CD013330-list-0025"> <li> <p>Recovery of kidney function</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid.</p> </li> </ul> </p> </section> </section> <section id="CD013330-sec-0094"> <h5 class="title">Surface‐modified versus standard double‐lumen catheter (based on identical geometry and flow design) </h5> <p>One study compared surface‐modified double‐lumen catheters with standard double‐lumen catheters (<a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>). </p> <section id="CD013330-sec-0095"> <h6 class="title">Circuit lifespan</h6> <p>Compared with a standard double‐lumen catheter, the use of a surface‐modified double‐lumen catheter may extend circuit lifespan (<a href="./references#CD013330-fig-0014" title="">Analysis 6.1</a> (1 study, 262 circuits): MD 16.00 hours, 95% CI 13.49 to 18.51; low certainty evidence). </p> </section> <section id="CD013330-sec-0096"> <h6 class="title">Death from any cause at day 28</h6> <p><a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a> reported ICU death. It is uncertain whether surface‐modified double‐lumen catheter reduced the risk of ICU deaths compared to standard double‐lumen catheter because the certainty of the evidence was very low (<a href="./references#CD013330-fig-0015" title="">Analysis 6.2</a> (1 study, 236 participants): RR 1.08, 95% CI 0.76 to 1.53; very low certainty evidence). </p> </section> <section id="CD013330-sec-0097"> <h6 class="title">Recovery of kidney function</h6> <p>Compared with a standard double‐lumen catheter, a surface‐modified double‐lumen catheter may not lead to the recovery of kidney function (<a href="./references#CD013330-fig-0016" title="">Analysis 6.3</a> (1 study, 236 participants): RR 0.91, 95% CI 0.70 to 1.20; low certainty evidence). </p> </section> <section id="CD013330-sec-0098"> <h6 class="title">Vascular access complications</h6> <p>Compared with standard double‐lumen catheters, surface‐modified double‐lumen catheters may make little or no difference to vascular access complications (<a href="./references#CD013330-fig-0017" title="">Analysis 6.4</a> (1 study, 236 participants): RR 0.32, 95% CI 0.08 to 1.20; low certainty evidence). </p> </section> <section id="CD013330-sec-0099"> <h6 class="title">Costs</h6> <p>Compared with standard double‐lumen catheters, surface‐modified double‐lumen catheters may lead to reduced medical costs (exchange costs of temporary catheters) (<a href="./references#CD013330-fig-0018" title="">Analysis 6.5</a> (1 study, 236 participants): MD ‐5508.00 USD, 95% CI ‐5612.98 to ‐5403.02; low certainty evidence) </p> </section> <section id="CD013330-sec-0100"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported.</p> <p> <ul id="CD013330-list-0026"> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid.</p> </li> </ul> </p> </section> </section> </section> <section id="CD013330-sec-0101"> <h4 class="title">Membrane types</h4> <section id="CD013330-sec-0102"> <h5 class="title">Polyethylenimine‐treated AN69 membrane (AN69ST) versus other membranes</h5> <p>Three studies compared AN69ST with other types of membranes as a non‐pharmacological intervention for preventing circuit clotting during CKRT (<a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>; <a href="./references#CD013330-bbs2-0020" title="YinY , ZhaoC , HuZ , WeiS , HuoY . The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2015;27(5):343-8. [MEDLINE: 26003637]">Yin 2015</a>). <a href="./references#CD013330-bbs2-0003" title="BromanME , HanssonF , VincentJL , BodelssonM . Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE [Electronic Resource]2019;14(8):e0220444. [MEDLINE: 31369593]">Broman 2019</a> but did not examine the prespecified outcome measures of this review. </p> <section id="CD013330-sec-0103"> <h6 class="title">Circuit lifespan</h6> <p>AN69ST may make little or no difference to circuit lifespan compared to other membranes (<a href="./references#CD013330-fig-0019" title="">Analysis 7.1</a> (2 studies, 56 circuits): MD 1.54 hours, 95% CI ‐4.53 to 7.60; I² = 0%; low certainty evidence). </p> </section> <section id="CD013330-sec-0104"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported in the three included studies.</p> <p> <ul id="CD013330-list-0027"> <li> <p>Death</p> </li> <li> <p>Recovery of kidney function</p> </li> <li> <p>Vascular access complications</p> </li> <li> <p>Costs</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid.</p> </li> </ul> </p> </section> </section> <section id="CD013330-sec-0105"> <h5 class="title">Flat plate versus hollow fibre filters of the same membrane type</h5> <p>One study compared flat plate and hollow fibre filters for preventing circuit clotting during CKRT (<a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a>). </p> <section id="CD013330-sec-0106"> <h6 class="title">Circuit lifespan</h6> <p>It is uncertain whether the use of a flat plate haemofilter extended circuit lifespan compared to hollow fibre filters as the certainty of the evidence was very low (<a href="./references#CD013330-fig-0020" title="">Analysis 8.1</a> (1 study, 38 participants): MD ‐1.40 hours, 95% CI ‐12.12 to 9.32). </p> <p>The following outcomes were not reported.</p> <p> <ul id="CD013330-list-0028"> <li> <p>Death</p> </li> <li> <p>Recovery of kidney function</p> </li> <li> <p>Vascular access complications</p> </li> <li> <p>Costs</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid</p> </li> </ul> </p> </section> </section> <section id="CD013330-sec-0107"> <h5 class="title">More and shorter hollow fibre filters versus standard filters</h5> <p>One study compared more and shorter hollow fibre filters with standard filters (<a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>). </p> <section id="CD013330-sec-0108"> <h6 class="title">Circuit lifespan</h6> <p>Compared with standard filters, the use of a filter with more and shorter hollow fibres may reduce circuit lifespan (<a href="./references#CD013330-fig-0021" title="">Analysis 9.1</a> (1 study, 6 participants): MD ‐5.87 hours, 95% CI ‐10.18 to ‐1.56; low certainty evidence). </p> <p>The following outcomes were not reported.</p> <p> <ul id="CD013330-list-0029"> <li> <p>Death</p> </li> <li> <p>Recovery of kidney function</p> </li> <li> <p>Vascular access complications</p> </li> <li> <p>Costs</p> </li> <li> <p>Types and number of dialysis filters, circuits, and catheters</p> </li> <li> <p>Consumption of dialysate/dialysis fluid</p> </li> </ul> </p> </section> </section> <section id="CD013330-sec-0109"> <h5 class="title">Filters with a larger membrane surface area versus a smaller membrane surface area</h5> <p><a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a> reported circuit lifespan did not differ between larger versus smaller membrane surface areas (15.8 hours (SE 14.3) versus 16.8 hours (SE 13.1), respectively). However, the precise numbers of participants involved in these two analyses were not reported. We contacted the corresponding author in an attempt to obtain additional information for further clarification, but the respective data were not available. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013330-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013330-sec-0110"></div> <section id="CD013330-sec-0111"> <h3 class="title" id="CD013330-sec-0111">Summary of main results</h3> <p>This review included 20 studies involving 1143 randomised participants receiving CKRT that reported the effects of a variety of non‐pharmacological interventions on circuit clotting‐related outcomes. Most of the included studies were judged to be at unclear risk of bias. All but one study involved adult participants. The causes of AKI varied across studies but the major cause (as indicated in 11 included studies) was sepsis. According to the GRADE approach, we found that the certainty of the available evidence regarding non‐pharmacological interventions for preventing clotting of extracorporeal circuits during CKRT was low to very low. CVVHDF (as compared with CVVH), pre‐dilution haemofiltration (as compared with post‐dilution haemofiltration), placing the tip of a longer catheter targeting the right atrium (as compared with placing a shorter catheter targeting the tip in the superior vena cava, and surface‐modified double‐lumen catheter (as compared with a standard catheter) may extend circuit lifespan. It is worth noting that the majority of the included studies reported findings on circuit lifespan but not death. </p> </section> <section id="CD013330-sec-0112"> <h3 class="title" id="CD013330-sec-0112">Overall completeness and applicability of evidence</h3> <p>We conducted the present review using standard Cochrane review methodology in order to present a comprehensive assessment of available evidence indicating the effects of non‐pharmacological interventions for preventing circuit clotting during CKRT; we included eligible studies irrespective of participants' age, sex, or underlying/primary conditions. Our approach yielded evidence on two primary outcomes and five secondary outcomes across 10 treatment comparisons. However, as our prespecified outcomes of interest were often not reported, we were only able to present limited evidence for a few outcomes in each comparison. Furthermore, only one RCT contributed to each estimate of circuit lifespan in the following comparisons: CVVHDF versus CVVH (<a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>), long versus short catheter (<a href="./references#CD013330-bbs2-0014" title="HoKM , MorganDJ . Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesthesia &amp; Intensive Care2014;42(1):59-64. [MEDLINE: 24471665]MorganD , HoK , MurrayC , DaviesH , LouwJ . A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases2012;60(2):272-9. [MEDLINE: 22497790]">RADICAL 2012</a>), surface‐modified versus standard double‐lumen catheter with identical geometry and flow design (<a href="./references#CD013330-bbs2-0011" title="MeierP , MeierR , TuriniP , FrioletR , BlancE . Prolonged catheter survival in patients with acute kidney injury on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification. Nephrology Dialysis Transplantation2011;26(2):628-35. [MEDLINE: 20667989]MeierP . Prolonged catheter survival in patients with acute kidney insufficiency on continuous renal replacement therapy using a less thrombogenic micropatterned polymer modification [abstract]. Hemodialysis International2009;13(3):416. [EMBASE: 70213431]">Meier 2011a</a>), flat plate versus hollow fibre filter of the same membrane type (<a href="./references#CD013330-bbs2-0002" title="BaldwinI , TanHK , BridgeN , BellomoR . Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Renal Failure2002;24(6):839-48. [MEDLINE: 12472205]">Baldwin 2002</a>), and more and shorter versus standard hollow fibre filter (<a href="./references#CD013330-bbs2-0007" title="DungenHD , vonHeymannC , RoncoC , KoxWJ , SpiesCD . Renal replacement therapy: physical properties of hollow fibers influence efficiency. International Journal of Artificial Organs2001;24(6):357-66. [MEDLINE: 11482501]">Dungen 2001</a>). For a number of comparisons, we found only one eligible study reporting the outcome measures of interest. Cross‐over studies, accounting for more than half of the included studies in this review, did not provide data from the first phase i.e. before crossing over. We thus decided instead to use the results of within‐group comparisons. Due to limited data, we could not perform predetermined subgroup or sensitivity analyses, nor did we identify sufficient numbers of studies to assess publication bias. We identified five ongoing studies (<a href="./references#CD013330-bbs2-0065" title="KoynerJ . Continuous venovenous hemofiltration versus continuous venovenuous hemodialysis [A comparison of the efficacy of continuous venovenous hemofiltration versus continuous venovenous hemodialysis for renal replacement therapy in acute kidney injury]. clinicaltrials.gov/ct2/show/NCT01062984 (first received 4 February 2010). ">NCT01062984</a>; <a href="./references#CD013330-bbs2-0066" title="ChuaHR . Efficacy and safety of heparin-grafted membrane for CRRT (CARROM) [Continuous renal replacement therapy with anticoagulation-free regimen in bleeding-risk patients using oXiris membrane - CARROM Study]. clinicaltrials.gov/ct2/show/NCT01779635 (first received 30 January 2013). ">NCT01779635</a>; <a href="./references#CD013330-bbs2-0067" title="RieraJS . Impact of CVVHD with adsorption capacity membranes in septic acute kidney injury [Impact of a continuous dialysis technique associated with adsorption capacity membranes in patients with sepsis associated - acute kidney injury]. clinicaltrials.gov/ct2/show/NCT01790620 (first received 13 February 2013). ">NCT01790620</a>; <a href="./references#CD013330-bbs2-0068" title="RimmeleT . Endotoxins and cytokines removal during continuous hemofiltration with oXiris (ECRO). clinicaltrials.gov/ct2/show/NCT03426943 (first received 8 February 2018). ">NCT03426943</a>; <a href="./references#CD013330-bbs2-0069" title="WeidhaseL , deFalloisJ , HausigE , KaiserT , MendeM , PetrosS . Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Critical Care (London, England)2020;24(1):644. [MEDLINE: 33176824]">Weidhase 2020</a>); of these, three planned to compare the modes of haemodialysis: CVVH, CVVHD, and CVVHDF (<a href="./references#CD013330-bbs2-0069" title="WeidhaseL , deFalloisJ , HausigE , KaiserT , MendeM , PetrosS . Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Critical Care (London, England)2020;24(1):644. [MEDLINE: 33176824]">Weidhase 2020</a>; <a href="./references#CD013330-bbs2-0065" title="KoynerJ . Continuous venovenous hemofiltration versus continuous venovenuous hemodialysis [A comparison of the efficacy of continuous venovenous hemofiltration versus continuous venovenous hemodialysis for renal replacement therapy in acute kidney injury]. clinicaltrials.gov/ct2/show/NCT01062984 (first received 4 February 2010). ">NCT01062984</a>; <a href="./references#CD013330-bbs2-0067" title="RieraJS . Impact of CVVHD with adsorption capacity membranes in septic acute kidney injury [Impact of a continuous dialysis technique associated with adsorption capacity membranes in patients with sepsis associated - acute kidney injury]. clinicaltrials.gov/ct2/show/NCT01790620 (first received 13 February 2013). ">NCT01790620</a>), but we were unable to identify any of our prespecified outcome measures in the study registers. <a href="./references#CD013330-bbs2-0066" title="ChuaHR . Efficacy and safety of heparin-grafted membrane for CRRT (CARROM) [Continuous renal replacement therapy with anticoagulation-free regimen in bleeding-risk patients using oXiris membrane - CARROM Study]. clinicaltrials.gov/ct2/show/NCT01779635 (first received 30 January 2013). ">NCT01779635</a> and <a href="./references#CD013330-bbs2-0068" title="RimmeleT . Endotoxins and cytokines removal during continuous hemofiltration with oXiris (ECRO). clinicaltrials.gov/ct2/show/NCT03426943 (first received 8 February 2018). ">NCT03426943</a> plan to examine the effects of AN69ST membrane, which falls into the scope of our review, on the circuit life and death. This information will be incorporated in future updates.  </p> <p>We are aware that the applicability of our review evidence is limited because the majority of the included studies were performed more than 10 years ago and, understandably, clinical practice in this field has since changed. As an example, a number of the included studies did not use specific treatment criteria but instead relied on physicians' judgment for the initiation of CKRT (<a href="./references#CD013330-bbs2-0005" title="DaviesHT , LeslieG , PereiraSM , WebbSA . A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. International Journal of Artificial Organs2008;31(3):221-7. [MEDLINE: 18373315]">Davies 2008</a>; <a href="./references#CD013330-bbs2-0008" title="FealyN , AitkenL , du ToitE , BaileyM , BaldwinI . Evaluation of urea and creatinine change during continuous renal replacement therapy: effect of blood flow rate. Critical Care &amp; Resuscitation2018;20(1):41-7. [MEDLINE: 29458320]FealyN , AitkenL , DuToitE , BaldwinI . Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a pilot randomised controlled trial [abstract]. Anaesthesia &amp; Intensive Care2016;44(2):305. [EMBASE: 72325668]FealyN , AitkenL , du ToitE , LoS , BaldwinI . Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial. Critical Care Medicine2017;45(10):e1018-25. [MEDLINE: 28658026]">Fealy 2017</a>; <a href="./references#CD013330-bbs2-0017" title="SchetzM , Van CromphautS , DuboisJ , Van den BergheG . Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?Intensive Care Medicine2012;38(11):1818-25. [MEDLINE: 22773036]">Schetz 2012</a>). Moreover, the appropriate timing of CKRT initiation is yet to be fully investigated (<a href="./references#CD013330-bbs2-0079" title="GaudryS , HajageD , BenichouN , ChaïbiK , BarbarS , ZarbockA , et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet2020;395(10235):1506-15. [MEDLINE: 32334654]">Gaudry 2020</a>; <a href="./references#CD013330-bbs2-0105" title="WaldR , BagshawSM . The timing of renal replacement therapy initiation in acute kidney injury: is earlier truly better?*. Critical Care Medicine2014;42(8):1933-4. [MEDLINE: 25029128]">Wald 2014</a>). Regional citrate anticoagulation has been widely used and it was recommended in international guidelines (<a href="./references#CD013330-bbs2-0088" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements2012;2(2):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO Acute Kidney Injury Work Group 2012</a>). The choice of anticoagulants should have an impact on the filter life in the current era. It should be highlighted that the evaluation of pharmacological interventions to prevent clotting is covered by a separate Cochrane review, as such, the findings from this review should be read in combination with the review on pharmacological interventions to prevent clotting of extracorporeal circuits during CKRT (<a href="./references#CD013330-bbs2-0100" title="TsujimotoH , TsujimotoY , NakataY , FujiiT , TakahashiS , AkazawaM , et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD012467. [DOI: 10.1002/14651858.CD012467.pub3]">Tsujimoto 2020</a>). </p> </section> <section id="CD013330-sec-0113"> <h3 class="title" id="CD013330-sec-0113">Quality of the evidence</h3> <p>We assessed the certainty of included randomised evidence using the GRADE approach (<a href="./references#CD013330-bbs2-0081" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">Guyatt 2008</a>). Overall, the certainty of our review evidence was judged to be low to very low due to the high risk of bias and small sample size amongst the included studies. For the majority of these studies, random sequence generation, allocation concealment, and blinding domains were assessed to be at unclear or high risk of bias (<a href="#CD013330-fig-0003">Figure 3</a>). The total numbers of participants in all meta‐analyses were less than the optimal information size of 400, as recommended by the GRADE framework (<a href="./references#CD013330-bbs2-0082" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence - Imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [MEDLINE: 21839614]">Guyatt 2011a</a>). With regards to the thresholds for appreciable treatment benefits and harms, we used a relative risk reduction of 0.25 for binary outcomes, and a standard deviation of 0.2 for continuous outcomes (<a href="./references#CD013330-bbs2-0074" title="CohenJ . Statistical power analysis for the behavioral sciences. 2nd edition. Hillsdale, NJ: Erlbaum, 1988.">Cohen 1988</a>; <a href="./references#CD013330-bbs2-0082" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence - Imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [MEDLINE: 21839614]">Guyatt 2011a</a>). Regarding the timing of mortality measurements, only one study in this review reported the prespecified 28‐day mortality and the others were downgraded for indirectness. As aforementioned, identified ongoing studies did not plan to include our review outcomes of interest and we judged that publication bias was highly unlikely. </p> </section> <section id="CD013330-sec-0114"> <h3 class="title" id="CD013330-sec-0114">Potential biases in the review process</h3> <p>We used the effect estimates from within‐group comparisons in the included cross‐over trials since outcome data from the first phase (before crossing over) were unavailable. However, it is unlikely that participant status before and after crossing over was similar since health conditions, in general, often change drastically within a short period of time in the ICU setting (<a href="./references#CD013330-bbs2-0089" title="LeloupM , BriatteI , LangloisA , CariouA , LesieurO , ACIR study group. Unexpected cardiac arrests occurring inside the ICU: outcomes of a French prospective multicenter study. Intensive Care Medicine2020;46(5):1005-15. [MEDLINE: 32152653]">Leloup 2020</a>). Additionally, one could foresee the circuit lifespan during the second phase (after crossing over) given that the study interventions were not blinded to study personnel or participants. This, in effect, might lead to the use of co‐interventions, such as saline flushes, in the second phase. Therefore, we explicitly considered baseline imbalance and co‐interventions as potential sources of 'Other risk of bias' as per the Cochrane Collaboration's tool for assessing the risk of bias (<a href="./references#CD013330-bbs2-0085" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). As a result, half of the included studies were judged to be at high or unclear risk of co‐interventions. The lack of adjustment for anticoagulation methods should also be acknowledged as a limitation of this review. Additionally, we did not consider censoring effect on circuit life as this often needs individual participant data. The robustness of our findings should be further confirmed by comparing survival censoring for not clotting or for catheter reasons. We were unable to locate study plans/protocols for numerous included studies and consequently rated the risk of reporting bias as unclear. <br/>  </p> </section> <section id="CD013330-sec-0115"> <h3 class="title" id="CD013330-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>A published non‐Cochrane systematic review included both RCTs and observational studies assessing the effects of non‐pharmacological interventions (<a href="./references#CD013330-bbs2-0072" title="BrainM , WinsonE , RoodenburgO , McNeilJ . Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrology2017;18(1):69. [MEDLINE: 28219324]">Brain 2017</a>). The review authors reported results similar to ours, where longer catheter or CVVHDF were superior in terms of prolonging circuit lifespan. On the other hand, as opposed to findings reported in <a href="./references#CD013330-bbs2-0072" title="BrainM , WinsonE , RoodenburgO , McNeilJ . Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrology2017;18(1):69. [MEDLINE: 28219324]">Brain 2017</a>, we found that higher blood flow exerted no effects on circuit lifespan. This might be due to the inclusion of non‐randomised evidence in <a href="./references#CD013330-bbs2-0072" title="BrainM , WinsonE , RoodenburgO , McNeilJ . Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrology2017;18(1):69. [MEDLINE: 28219324]">Brain 2017</a>. It should be noted that the included trials examined higher blood flow versus standard blood flow. As such, lowering the blood flow rate below the target, which is based on filtration fraction when filtration is used is not recommended for improving circuit life in this review. However, as mentioned above, our review outcomes, including death due to any cause and kidney function recovery, were often not reported. </p> <p><a href="./references#CD013330-bbs2-0072" title="BrainM , WinsonE , RoodenburgO , McNeilJ . Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrology2017;18(1):69. [MEDLINE: 28219324]">Brain 2017</a> assessed the effects of several non‐pharmacological interventions that intended to prolong circuit life on several outcomes, such as different access sites and types of catheters however, the evidence came from observational studies and it was not our intention to consider observational studies in this review. It is worth highlighting some novel findings presented in this Cochrane review, where the surface‐modified double‐lumen catheter (as compared with standard double‐lumen catheter and the use of a long catheter (as compared with a short catheter) are generally cheaper and may prolong circuit lifespan. </p> <p>As for the other included non‐pharmacological interventions, the currently available evidence is insufficient to allow for comprehensive assessment on the effects of a non‐pharmacological approach on circuit clotting as well as prognosis for people with AKI undergoing CKRT. We would like to highlight that a major strength of our review is adopting the robust Cochrane methodology during the entire review development process, in particular the use of a prespecified protocol as well as the GRADE approach to assess of certainty of evidence. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013330-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013330-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013330-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013330-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CVVHD versus CVVH or CVVHDF, Outcome 1: Death from any cause" data-id="CD013330-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: CVVHD versus CVVH or CVVHDF, Outcome 1: Death from any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CVVHD versus CVVH or CVVHDF, Outcome 2: Recovery of kidney function" data-id="CD013330-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: CVVHD versus CVVH or CVVHDF, Outcome 2: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CVVHDF versus CVVH, Outcome 1: Circuit lifespan" data-id="CD013330-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: CVVHDF versus CVVH, Outcome 1: Circuit lifespan</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CVVHDF versus CVVH, Outcome 2: Death from any cause at 28 days" data-id="CD013330-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: CVVHDF versus CVVH, Outcome 2: Death from any cause at 28 days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CVVHDF versus CVVH, Outcome 3: Recovery of kidney function" data-id="CD013330-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: CVVHDF versus CVVH, Outcome 3: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pre‐dilution versus post dilution (as defined by study investigators), Outcome 1: Circuit lifespan" data-id="CD013330-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Pre‐dilution versus post dilution (as defined by study investigators), Outcome 1: Circuit lifespan </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Higher blood flow versus standard blood flow, Outcome 1: Circuit lifespan" data-id="CD013330-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Higher blood flow versus standard blood flow, Outcome 1: Circuit lifespan</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter, Outcome 1: Circuit lifespan" data-id="CD013330-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter, Outcome 1: Circuit lifespan </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter, Outcome 2: Death from any cause at 28 days" data-id="CD013330-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter, Outcome 2: Death from any cause at 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter, Outcome 3: Vascular access complications" data-id="CD013330-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter, Outcome 3: Vascular access complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 1: Circuit lifespan" data-id="CD013330-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 1: Circuit lifespan </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 2: Death from any cause at 28 days" data-id="CD013330-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 2: Death from any cause at 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 3: Recovery of kidney function" data-id="CD013330-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 3: Recovery of kidney function </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 4: Vascular access complications" data-id="CD013330-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 4: Vascular access complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 5: Costs" data-id="CD013330-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design, Outcome 5: Costs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Polyethylenimine‐treated AN69 membrane (AN69ST) versus other membrane, Outcome 1: Circuit lifespan" data-id="CD013330-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Polyethylenimine‐treated AN69 membrane (AN69ST) versus other membrane, Outcome 1: Circuit lifespan </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Flat plate versus hollow fibre filter of the same membrane type, Outcome 1: Circuit lifespan" data-id="CD013330-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Flat plate versus hollow fibre filter of the same membrane type, Outcome 1: Circuit lifespan </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013330-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/urn:x-wiley:14651858:media:CD013330:CD013330-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: More and shorter versus standard hollow fibre filter of the same membrane type, Outcome 1: Circuit lifespan" data-id="CD013330-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_t/tCD013330-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: More and shorter versus standard hollow fibre filter of the same membrane type, Outcome 1: Circuit lifespan </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/media/CDSR/CD013330/image_n/nCD013330-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CVVHD versus CVVH or CVVHDF for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CVVHD compared to CVVH or CVVHDF for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting: </b> ICU<br/><b>Intervention:</b> CVVHD<br/><b>Comparison:</b> CVVH or CVVHDF </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVH or CVVHDF</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVHD</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Circuit lifespan</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause</p> <p>Follow up: 24 hours to 90 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1,000<br/>(225 to 751) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77<br/>(0.42 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> <p>Follow up: ICU discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1,000<br/>(67 to 402) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/>(0.37 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CVVHD:</b> continuous venovenous haemodialysis; <b>CVVH:</b> continuous venovenous haemofiltration; <b>CVVHDF:</b> continuous venovenous haemodiafiltration; <b>CKRT:</b> continuous kidney replacement therapy;<b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval;<b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious inconsistency </p> <p><sup>3</sup> Downgraded one level due to serious indirectness (death at the longest follow‐up) </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CVVHD versus CVVH or CVVHDF for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CVVHDF versus CVVH for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CVVHDF versus CVVH for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> CVVHDF<br/><b>Comparison:</b> CVVH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVVHDF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with CVVH was 8.55 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with CVVHDF was 10.15 hours higher (5.15 to 15.15 higher) than CVVH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1,000<br/>(316 to 547) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.52 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>714 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>786 per 1,000<br/>(614 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/>(0.86 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>2,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CVVHD:</b> continuous venovenous haemodialysis; <b>CVVH:</b> continuous venovenous haemofiltration; CKRT: continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> <p><sup>3</sup> Downgraded one level due to serious concern of publication bias </p> <p><sup>4</sup> Downgraded two levels due to very serious risk of bias (participants were excluded from analyses if died) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CVVHDF versus CVVH for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pre‐dilution versus post‐dilution (as defined by study investigators) for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Pre‐dilution versus post‐dilution (as defined by study investigators) for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> pre‐dilution<br/><b>Comparison:</b> post‐dilution </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with post‐dilution</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pre‐dilution</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with post‐dilution was 22.5 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with pre‐dilution was 9.34 hours higher (2.60 lower to 21.29 higher) than post‐dilution </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pre‐dilution versus post‐dilution (as defined by study investigators) for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Higher blood flow versus standard blood flow for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Higher versus standard blood flow for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> higher blood flow<br/><b>Comparison:</b> standard blood flow </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard blood flow</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with higher blood flow</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with standard blood flow was 17.2 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with higher blood flow was 0.64 hours higher (3.37 lower to 4.64 higher) than standard blood flow </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious inconsistency </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Higher blood flow versus standard blood flow for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Long (&gt; 20 cm) versus short (≤ 20 cm) catheter for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Long (&gt; 20 cm) versus short (≤ 20 cm) catheter for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> long catheter (&gt; 20 cm)<br/><b>Comparison:</b> short catheter (≤ 20 cm) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with short catheter (≤ 20cm)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with long catheter (&gt; 20 cm)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with short catheters was 17.5 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with longer catheters was 6.5 hours higher (1.48 to 11.52 higher) than short catheters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>402 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1,000<br/>(104 to 529) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38<br/>(0.61 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular access complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>511 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1,000<br/>(102 to 368) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.38<br/>(0.20 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious indirectness (used ICU death as a surrogate endpoint) </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision </p> <p><sup>4</sup> Downgraded one level due to serious imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Long (&gt; 20 cm) versus short (≤ 20 cm) catheter for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> surface‐modified double‐lumen catheter<br/><b>Comparison:</b> standard double‐lumen catheter with identical geometry and flow design </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard double‐lumen catheter with identical geometry and flow design</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surface‐modified, double‐lumen catheter</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with standard double‐lumen catheters was 118 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with surface‐modified double‐lumen catheters was 16 hours higher (13.49 to 18.51 higher) than standard double‐lumen catheters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>331 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1,000<br/>(251 to 506) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08<br/>(0.76 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Very low <sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>492 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1,000<br/>(344 to 590) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/>(0.70 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular access complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000<br/>(7 to 92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/>(0.09 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> <p><sup>3</sup> Downgraded one level due to serious indirectness (used ICU mortality as a surrogate) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Polyethylenimine‐treated membrane (AN69ST) versus other membranes for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Polyethylenimine‐treated AN69ST versus other membranes for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> polyethylenimine‐treated AN69ST<br/><b>Comparison:</b> other membranes </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with other membrane</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polyethylenimine‐treated AN69ST</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with other membranes was 14.1 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with polyethylenimine‐treated AN69ST was 1.54 hours higher (4.53 lower to 7.6 higher) than other membranes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>a</sup> we calculated circuit lifespan per circuit<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Polyethylenimine‐treated membrane (AN69ST) versus other membranes for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Flat plate versus hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Flat plate versus hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AKI receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> flat plate filter<br/><b>Comparison:</b> hollow fibre filter (of the same membrane type) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hollow fibre filter of the same membrane type</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with flat plate filter</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with hollow fibre filters was 17.1 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with flat plate filters was 1.4 hours lower (12.12 lower to 9.32 higher) than hollow fibre filters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of kidney function</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular access complications</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Flat plate versus hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013330-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">More and shorter versus standard hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>More and shorter versus standard hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI patients receiving CKRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> more and shorter hollow fibre filter<br/><b>Comparison:</b> standard hollow fibre filter </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard hollow fibre filter of the same membrane type</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with more and shorter fibre filters</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Circuit lifespan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with standard hollow fibre filters was 21.27 hours</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean circuit lifespan with more and shorter fibre filters was 5.87 hours lower (10.18 to 1.56 lower) than standard hollow fibre filters </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from any cause at day 28 of follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular access complications</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKRT:</b> continuous kidney replacement therapy; <b>AKI:</b> acute kidney injury; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">More and shorter versus standard hollow fibre filter of the same membrane type for preventing clotting of extracorporeal circuits during CKRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/full#CD013330-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CVVHD versus CVVH or CVVHDF</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death from any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.41, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Death at 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.05, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Death at 60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.66, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Death at 90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.23, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Death in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.79, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.37, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CVVHD versus CVVH or CVVHDF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CVVHDF versus CVVH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.15 [5.15, 15.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Death from any cause at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.86, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CVVHDF versus CVVH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pre‐dilution versus post dilution (as defined by study investigators)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.34 [‐2.60, 21.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pre‐dilution versus post dilution (as defined by study investigators)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Higher blood flow versus standard blood flow</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [‐3.37, 4.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Higher blood flow versus standard blood flow</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.50 [1.48, 11.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Death from any cause at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.61, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Vascular access complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.20, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Longer (&gt; 20 cm) versus shorter (≤ 20 cm) catheter</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.00 [13.49, 18.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Death from any cause at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.76, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Vascular access complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Costs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.51 [‐5.61, ‐5.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Surface‐modified versus standard double‐lumen catheter with identical geometry and flow design</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Polyethylenimine‐treated AN69 membrane (AN69ST) versus other membrane</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [‐4.53, 7.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Polyethylenimine‐treated AN69 membrane (AN69ST) versus other membrane</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Flat plate versus hollow fibre filter of the same membrane type</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐12.12, 9.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Flat plate versus hollow fibre filter of the same membrane type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013330-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">More and shorter versus standard hollow fibre filter of the same membrane type</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Circuit lifespan <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.87 [‐10.18, ‐1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">More and shorter versus standard hollow fibre filter of the same membrane type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013330.pub2/references#CD013330-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013330.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013330-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013330-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013330-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013330-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013330-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013330-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013330-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013330\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013330\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013330\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013330\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013330\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013330.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013330.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013330.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013330.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013330.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717472714"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013330.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717472718"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013330.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db8c15a919365',t:'MTc0MDcxNzQ3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 